[["index.html", "PREVENT-MINS PROTOCOL 1 Skrócony protokół badania 1.1 Wstęp i uzasadnienie badania 1.2 Plan badania 1.3 Kryteria włączenia i wyłączenia z badania PREVENT-MINS 1.4 Rekrutacja pacjentów oraz świadoma zgoda na udział w badaniu 1.5 Randomizacja 1.6 Procedury przewidziane w ramach badania 1.7 Interwencje badawcze 1.8 Minimalizacja ryzyka, monitorowanie oraz strategia radzenia sobie z potencjalnymi problemami 1.9 Obserwacja uczestników badania 1.10 Punkty końcowe 1.11 Analiza statystyczna 1.12 Raportowanie występowania działań niepożądanych oraz poważnych działań niepożądanych 1.13 Pozostałe kwestie związane z badaniem", " PREVENT-MINS PROTOCOL Ośrodek Intensywnej Terapii i Medycyny Okołozabiegowej Collegium Medicum Wersja 06.04.2022 1 Skrócony protokół badania Iwabradyna w zapobieganiu uszkodzeniu mięśnia sercowego po operacjach pozasercowych - badanie PREVENT-MINS. Wersja 2.1 z dnia 10.03.2022 Tytuł: Iwabradyna w zapobieganiu uszkodzeniu mięśnia sercowego po operacjach pozasercowych - badanie PREVENT-MINS. Projekt badania: Wieloośrodkowe, randomizowane, podwójnie zaślepione, kontrolowane placebo badanie iwabradyny jako leczenia skojarzonego z leczeniem standardowym. Wielkość próby: 2500 pacjentów. Cele pierwszorzędowe: Określenie wpływu okołooperacyjnego podania iwabradyny u pacjentów z chorobami związanymi z miażdżycą lub w grupie ryzyka wystąpienia tych chorób, poddawanych zabiegom pozasercowym. Pierwotnym punktem końcowym jest uszkodzenie mięśnia sercowego po operacji pozasercowej (ang. myocardial injury after noncardian surgery; MINS) zdefiniowane jako dowolny zawał mięśnia sercowego oraz dowolne podwyższone pooperacyjne stężenie troponiny sercowej będące następstwem niedokrwienia mięśnia sercowego w trakcie lub w ciągu 30 dni po operacji pozasercowej. Cele drugorzędowe: Określenie wpływu iwabradyny na częstość występowania następujących punktów końcowych w obserwacji 30-dniowej po zabiegu: złożony punkt końcowy obejmujący zgon z przyczyn naczyniowych, MINS niezakończone zgonem, udar mózgu niezakończony zgonem oraz zatrzymanie krążenia niezakończone zgonem; zgon z przyczyny naczyniowej; MINS niespełniające kryteriów zawału mięśnia sercowego zawartych w 4. uniwersalnej definicji zawału mięśnia sercowego (MI); zawał mięśnia sercowego; szczytowe stężenie troponiny sercowej; całkowite stężenie troponiny sercowej; liczba dni, które pacjent przeżył będąc w domu; udar mózgu; zgon z dowolnej przyczyny; jakość życia związana ze stanem zdrowia; odwołanie/odłożenie w czasie operacji w dniu zabiegu ze względu na obawy związane z częstością akcji serca; istotne kliniczne migotanie przedsionków; istotna klinicznie bradykardia; istotna klinicznie hipotensja oraz fosfeny. Cele trzeciorzędowe: Określenie wpływu iwabradyny na częstość występowania następujących punktów końcowych w obserwacji:1) 30-dniowej: zabieg rewaskularyzacji naczyń wieńcowych; rehospitalizacja z przyczyn naczyniowych; ostre uszkodzenie mięśnia sercowego spełniające kryteria zawarte w 4. uniwersalnej definicji zawału mięśnia sercowego; zatrzymanie krążenia niezakończone zgonem; ostra zastoinowa niewydolność serca; zakrzepica żył głębokich/zatorowość płucna; poważne krwawienie zgodnie z definicją Międzynarodowego Towarzystwa Zakrzepicy i Hemostazy (ISTH); krwawienie niezależnie związane ze śmiertelnością po zabiegu pozasercowym; sepsa; ostre uszkodzenie nerek spełniające kryteria KDIGO; ostre uszkodzenie nerek wymagające stosowania dializoterapii; amputacja; liczba dni poza oddziałem intensywnej terapii; czas hospitalizacji; czas pobytu w oddziale intensywnej terapii; destynacja wypisu2) rocznej: zgon z dowolnej przyczyny; zgon z przyczyny naczyniowej; zawał mięśnia sercowego; zabieg rewaskularyzacji naczyń wieńcowych; zatrzymanie akcji serca niezakończone zgonem; udar mózgu; jakość życia związana ze stanem zdrowia; amputacja; rehospitalizacja z przyczyn naczyniowych; Schemat leczenia: Pacjenci spełniający kryteria hemodynamiczne otrzymają 5 mg iwabradyny drogą doustną lub odpowiadające jej placebo w skojarzeniu ze standardowym leczeniem. Lek będzie podawany dwa razy dziennie od ≥1 godziny przed zabiegiem do siódmego dnia po operacji lub wypisu ze szpitala (jeśli nastąpi wcześniej) Obserwacja: 30 dni oraz 1 rok. Główny badacz Prof. dr hab. n. med. Wojciech Szczeklik Adres: ul. Wrocławska 1-3, 30-901 Kraków, Polska Email: wojciech.szczeklik@uj.edu.pl Ośrodek koordynujący Nazwa: Ośrodek Intensywnej Terapii i Medycyny Okołozabiegowej Collegium Medicum UJ Adres: ul. Wrocławska 1-3, 30-901 Kraków, Polska Email: prevent@uj.edu.pl Komitet sterujący: Prof. dr hab. n. med. Wojciech Szczeklik Prof. Philip J. Devereaux MD, PhD dr n. med. Anna Włudarczyk lek. Jakub Fronczek Udział sponsorów badania Badanie zostanie zaprojektowane, przeprowadzone, a uzyskane dane zostaną zanalizowane, zaprezentowane oraz opublikowane przez badaczy niezależnie od sponsorów. 1.1 Wstęp i uzasadnienie badania 1.1.1 Jakie jest znaczenie uszkodzenia mięśnia sercowego po zabiegu pozasercowym? Na świecie co roku wykonuje się ponad 230 milionów zabiegów pozasercowych i liczba ta stale wzrasta. W kohortowym badaniu the Vascular events In noncardiac Surgery patIents cOhort evaluatioN (VISION), obejmującym ponad 40 000 pacjentów w wieku ≥45 lat poddawanych zabiegom pozasercowym, udowodniono, że uszkodzenie mięśnia sercowego po zabiegu pozasercowym (ang. myocardial injury after noncardiac surgery, MINS), definiowane jako zwiększenie stężenia troponiny sercowej w ciągu 30 dni od zabiegu jest związane z niekorzystną prognozą, niezależnie od obecności innych cech świadczących o niedokrwieniu mięśnia sercowego. Diagnozę MINS postawiono u 18% uczestników badania VISION, z których ponad 90% nie prezentowało typowych objawów dławicowych. Zaobserwowano ponadto, że 1,8% uczestników badania zmarła w ciągu 30 dni od operacji, a za 13% tych zgonów odpowiadał właśnie MINS. Co więcej, aż jeden na siedmiu pacjentów, u których dochodzi do MINS, rozwija poważne powikłania naczyniowe w obserwacji długoterminowej. Zatem, MINS jest zjawiskiem stosunkowo częstym oraz wiąże się z poważnymi następstwami w obserwacji długoterminowej. 1.1.2 Czy istnieje związek pomiędzy częstotliwością akcji serca oraz występowaniem powikłań okołozabiegowych? Dane z badania VISION pokazują jasną zależność pomiędzy zwiększoną częstotliwością akcji serca, a częstością występowania MINS (OR 1,48; 95% CI 1,23–1,77), zawału mięśnia sercowego (OR 1,71; 95% CI 1,34–2,18) oraz śmiertelnością (OR 3,16; 95%CI 2,45–4,07). 1.1.3 Czy leki obniżające częstotliwość akcji serca zmniejszają częstość występowania powikłań okołozabiegowych? Metaanaliza randomizowanych badań klinicznych wysokiej jakości z wykorzystaniem β-blokerów w okresie okołozabiegowym, obejmująca 10 529 pacjentów, wykazała redukcję częstości zawału mięśnia sercowego niezakończonego zgonem (RR 0,73; 95%CI 0,61-0,88) przy zwiększonej śmiertelności 30-dniowej (RR 1,27; 95%CI 1,01-1,60) oraz częstszym występowaniu udaru mózgu (RR 1,73, 95%CI 1,00-2,99) oraz hipotensji (RR 1,51, 95%CI 1,37-1,67). Pogłębiona analiza zgromadzonych dowodów wskazuje, że zwiększona śmiertelność po podaniu β-blokerów przed zabiegiem pozasercowym prawdopodobnie jest następstwem zwiększonej częstości występowania istotnej klinicznie hipotensji w grupie interwencyjnej w porównaniu do grupy kontrolnej. Potencjalna korzyść wynikająca z obniżenia częstotliwości akcji serca stanowiła element uzasadniający zastosowanie klonidyny w randomizowanym badaniu POISE-2. Mechanizm działania klonidyny jest złożony i obejmuje zarówno obniżenie częstotliwości akcji serca, jak i obniżenie ciśnienia tętniczego poprzez oddziaływanie na autonomiczny układ nerwowy. W badaniu POISE-2 nie zdołano jednak wykazać zmniejszenia częstości występowania pierwotnego punktu końcowego (złożony punkt końcowy obejmujący zgon oraz zawał mięśnia sercowego niezakończony zgonem) w grupie interwencyjnej w porównaniu do placebo z HR=1,08 (95% CI 0,93-1,26). Podobnie jak w pierwszym badaniu POISE stwierdzono wyższą częstość istotnej klinicznie hipotensji u chorych przyjmujących klonidynę (HR 1,32; 95% CI, 1,24-1,40). Co istotne, u pacjentów w grupie interwencyjnej częściej dochodziło do nagłego zatrzymania krążenia niezakończonego zgonem (HR 3,20; 95% CI, 1,17-8,73). 1.1.4 Dlaczego w badaniu PREVENT-MINS zastosowana zostanie iwabradyna? Dostępne wyniki badań sugerują, że idealny lek zapobiegający okołooperacyjnym powikłaniom sercowym powinien obniżać częstotliwość akcji serca, jednocześnie pozostając bez wpływu na ciśnienie tętnicze krwi. Obie te cechy posiada właśnie iwabradyna, lek o znanym profilu bezpieczeństwa, stosowany od wielu lat u pacjentów obciążanych czynnikami ryzyka sercowo-naczyniowego. Iwabradyna charakteryzuje się wybiórczym i swoistym działaniem na prąd If w komórkach węzła zatokowego. Iwabradyna selektywnie obniża częstotliwość akcji serca, nie powodując obniżenia ciśnienia tętniczego krwi. Do najczęstszych działań niepożądanych iwabradyny zalicza się bradykardię oraz fosfeny (przemijające wrażenia widzenia silnego światła w części pola widzenia). Iwabradyna jest z powodzeniem stosowania u pacjentów z przewlekłym zespołem wieńcowym i/lub przewlekłą niewydolnością serca. Istnieją także przesłanki naukowe wskazujące na korzyści ze stosowania iwabradyny w okresie okołozabiegowym u chorych poddawanych m.in. zabiegom kardiochirurgicznym oraz planowym przezskórnym interwencjom wieńcowym. W przeprowadzonych dotychczas dwóch niewielkich badaniach wykazano, że zastosowanie iwabradyny w okresie okołozabiegowym u pacjentów poddawanych zabiegom pozasercowym powoduje spadek częstotliwości akcji serca bez zwiększania częstości istotnej klinicznie hipotensji. Dowody dotyczące jej wpływu na częstość występowania powikłań okołozabiegowych pozostają niejasne. 1.1.5 Dlaczego przeprowadzenie badania PREVENT-MINS jest istotne? Pomimo rozwoju anestezjologii i medycyny okołozabiegowej w ostatnich latach, śmiertelność w okresie 30 dni po zabiegach pozasercowych utrzymuje się na stałym poziomie. Jednym z czynników o udowodnionym związku z częstością poważnych powikłań sercowych jest podwyższona częstotliwość akcji serca. Dane pochodzące z badań klinicznych z randomizacją sugerują, że obniżenie częstotliwości akcji serca w okresie okołozabiegowym może mieć korzystny wpływ na wyniki leczenia. Wstępne dowody wskazują, że iwabradyna zwalnia akcję serca w podobnym stopniu jak β-blokery, jednak charakteryzuje się lepszym profilem bezpieczeństwa z punktu widzenia częstości występowania hipotensji i udarów mózgu w okresie okołozabiegowym. Badanie PREVENT-MINS oceni skuteczność iwabradyny w redukcji częstości MINS w populacji pacjentów obciążonych wysokim ryzykiem wystąpienia powikłań związanych z miażdżycą. 1.2 Plan badania 1.2.1 Cele badania Głównym celem badania PREVENT-MINS jest określenie czy okołooperacyjne zastosowanie iwabradyny jest skuteczniejsze niż placebo w redukcji częstości występowania MINS w ciągu 30 dni od randomizacji u pacjentów poddawanych zabiegom pozasercowym z rozpoznaną chorobą związaną z miażdżycą lub narażonych na jej wystąpienie. 1.2.2 Projekt badania Badanie PREVENT-MINS jest wieloośrodkowym badaniem klinicznym z randomizacją, do którego zrekrutowanych zostanie 2500 pacjentów z chorobą związaną z miażdżycą lub narażonych na jej wystąpienie. Uczestnicy badania zostaną zrandomizowani do grupy przyjmującej iwabradynę lub placebo w okresie okołozabiegowym, z równym przydziałem pacjentów do obu grup. Pacjenci, personel medyczny, osoby odpowiedzialne za gromadzenie danych naukowych, osoby oceniające punkty końcowe oraz badacze zostaną zaślepieni względem przynależności pacjenta do grupy interwencyjnej lub kontrolnej. 1.2.3 Wielkość próby Na podstawie wyników badania VISION szacujemy, że pierwotny punkt końcowy wystąpi u 18% pacjentów w grupie kontrolnej. W oparciu o wyniki meta-analizy obejmującej wyniki badania POISE oraz dowody z randomizowanych badań klinicznych wskazujące, że iwabradyna najpewniej charakteryzuje się podobnym działaniem przeciwniedokrwiennym jak β-blokery, szacujemy, że w grupie interwencyjnej MINS wystąpi u 13,5% pacjentów. Włączenie 2500 pacjentów pozwoli na wykrycie względnej redukcji ryzyka na poziomie 25% przy α=0,05 i β&lt;20%. 1.3 Kryteria włączenia i wyłączenia z badania PREVENT-MINS Kryteria włączenia Kryteria wyłączenia Pacjenci kwalifikują się, jeśli spełniają wszystkie poniższe kryteria: 1. Pacjent jest poddawany operacji pozasercowej; 2. Wiek≥45 lat; 3. Przewiduje się, że po operacji pozasercowej pacjent będzie przebywać w szpitalu przynajmniej przez noc; 4. Pacjent wyraża pisemną świadomą zgodę na udział w badaniu PREVENT-MINSORAZ5. Pacjent spełnia ≥1 z następujących 5 kryteriów (A-E): A. Dodatni wywiad w kierunku choroby wieńcowej;B. Dodatni wywiad w kierunku choroby tętnic obwodowych;C. Wywiad udaru;D. Pacjent poddawany jest dużej operacji naczyniowej LUB E. Dowolne 3 z 9 wymienionych kryteriów ryzyka: i. Pacjent poddawany jest dużemu zabiegowi (tj. zabiegi wewnątrzotrzewnowe, zabiegi chirurgii klatki piersiowej, zabiegi w przestrzeni zaotrzewnowej, duże zabiegi ortopedyczne); ii. Wywiad zastoinowej niewydolności serca;iii. Wywiad przejściowego ataku niedokrwiennego; iv. Wywiad cukrzycy i aktualne przyjmowanie leku przeciwcukrzycowego; v. Wiek ≥70 lat; vi. Wywiad nadciśnienia; vii. Kreatynina w surowicy &gt;175 μmol/l (&gt;2.0 mg/dl) w oparciu o najnowsze dostępne wyniki badań sprzed randomizacji; viii. Historia palenia w ciągu 2 lat przed zabiegiem; ix. Chory poddawany pilnej/nagłej operacji rozumianej jako operacja, której chirurg podejmuje się w ciągu 48 godzin od pojawienia się pacjenta w szpitalu. Pacjenci nie kwalifikują się, jeśli spełniają którekolwiek z poniższych kryteriów:1. Wcześniejsze uczestnictwo w badaniu PREVENT-MINS; 2. Rozpoznana alergia lub nadwrażliwość na iwabradynę; 3. Niedawne stosowanie iwabradyny (&lt;1 miesiąca); 4. Kobiety w wieku rozrodczym, które odmawiają stosowania wysoko skutecznej formy antykoncepcji;5. Niezdolność do połknięcia tabletki zawierającej badany lek; 6. Co najmniej jedno z niżej wymienionych znalezisk w badaniu klinicznym: A. spoczynkowa częstotliwość akcji serca &lt;65;B. skurczowe ciśnienie tętnicze &lt;90 mmHg;C. rytm niezatokowy; blok zatokowo-przedsionkowy lub blok przedsionkowo-komorowy (drugiego i trzeciego stopnia), zespół chorego węzła zatokowego, zespół długiego QT, zależność od rozrusznika serca, po przeszczepieniu serca (lub obecność na liście oczekujących); D. stosowanie wybranego leku przeciwarytmicznego klasy I lub III (chinidyna, dyzopiramid, sotalol, ibutilid, amiodaron) lub diltiazem/werapamil; E. ostre zespoły wieńcowe w ciągu 2 miesięcy przed operacją; F. ostra niewyrównana niewydolność serca, wstrząs kardiogenny, ostre zapalenie mięśnia sercowego; G. rozpoznana ciężka choroba wątroby lub nerek (klirens kreatyniny MDRD &lt;15 ml/min); H. udar lub przejściowe niedokrwienie mózgu w ciągu ostatnich 4 tygodni; LUB7. Małe ryzyko powikłań związanych z zabiegiem w ocenie badacza;8. Brak wiarygodności pacjenta w kontekście spełnienia niezbędnych wymogów dotyczących zgodności z protokołem badania w ocenie badacza. 1.4 Rekrutacja pacjentów oraz świadoma zgoda na udział w badaniu Pacjenci kwalifikowani do zabiegu w trybie planowym będą oceniani pod kątem spełnienia kryteriów włączenia do badania przez członków personelu badania w czasie osobistej wizyty przed zabiegiem. Jeżeli chory spełnia kryteria włączenia, członek personelu lub pielęgniarka zatrudniona w badaniu PREVENT-MINS oceni, czy chory wyraża chęć udziału w badaniu i po uzyskaniu odpowiedzi twierdzącej zbierze świadomą pisemną zgodę przed wdrożeniem jakichkolwiek procedur przewidzianych w protokole badania. Pacjenci spełniający kryteria badania zostaną dokładnie zbadani przez badacza PREVENT-MINS, zebrany zostanie dokładny wywiad lekarski (choroby przewlekłe, dane demograficzne) oraz wykonane zostanie 12-odprowadzeniowe EKG. 1.5 Randomizacja Po zebraniu pisemnej świadomej zgody pacjent zostanie włączony do badania i zrandomizowany z wykorzystaniem systemu Interactive Web Randomization System (IWRS). Zastosowana zostanie randomizacja blokowa ze stratyfikacją według ośrodka. Pacjenci zostaną zrandomizowani do grupy przyjmującej badany lek lub placebo w stosunku 1:1. 1.6 Procedury przewidziane w ramach badania Doba „0” Doba 1 Doba 2 Doba 3 Wypis ze szpitala Wizyta obserwacyjna (po 30 dniach) Wizyta obserwacyjna (po roku) Punkt czasowy Włączenie do badania Randomizacja Ocena kryteriów włączenia i wyłączenia X Świadoma zgoda X Randomizacja X Dane demograficzne X Historia medyczna X Pobranie próbki krwi X X X X Zabezpieczenie próbek do Biobanku X X Podstawowe badania laboratoryjne: - morfologia krwi- glukoza we krwi - potas w surowicy- sód w surowicy - APTT, PT (INR) X (PSO) Dodatkowe badania laboratoryjne: CRP X X NT-proBNP X X Troponina (hs cTnT lub hs cTnI) X X X X Kreatynina w surowicy X X Morfologia krwi X EKG X X* X* X* ECHO X** Szczegóły zabiegu X X Parametry życiowe X X X X X Kwestionariusz QOL X x x Skale: ASA, DASI, CFS X Ocena punktów końcowych X X X X X X PSO – procedury w ramach standardowej opieki okołooperacyjnej *w przypadku podwyższonych wartości troponin sercowych **u pacjentów z podwyższonymi wartościami troponin sercowych i zmianami w zapisie EKG, maksymalnie 1 badanie w trakcie hospitalizacji 1.7 Interwencje badawcze Pacjenci spełniający kryteria hemodynamiczne (skurczowe ciśnienie tętnicze ≥90 mmHg oraz rytm zatokowy z częstotliwością akcji serca ≥65 uderzeń/minutę) otrzymają tabletkę zawierającą 5 mg iwabradyny (grupa interwencyjna) lub analogiczną tabletkę zawierającą placebo (grupa kontrolna) w skojarzeniu ze standardowym leczeniem co najmniej 1 godzinę przed zabiegiem, a pierwsza dawka pooperacyjna zostanie podana wieczorem lub w godzinach porannych po zabiegu operacyjnym, jednak co najmniej 12 godzin po dawce przedoperacyjnej przy założeniu, że skurczowe ciśnienie tętnicze wynosi ≥90 mmHg, a częstotliwość akcji serca ≥65 uderzeń/minutę. Począwszy od dnia po zabiegu pacjent rozpocznie leczenie iwabradyną w dawce 5 mg w postaci doustnej lub placebo podawaną dwa razy dziennie, trwające przez maksymalnie 7 dni po zabiegu lub do wypisu ze szpitala. Jeżeli u chorego wystąpi migotanie lub trzepotanie przedsionków badany lek zostanie wstrzymany do czasu powrotu pacjenta do rytmu zatokowego. Tabletki zawierające placebo będą podobne do tabletek zawierających substancję czynną (5 mg iwabradyny). 1.8 Minimalizacja ryzyka, monitorowanie oraz strategia radzenia sobie z potencjalnymi problemami Strategia minimalizacji ryzyka związanego z podawaniem iwabradyny: 1. Pacjenci muszą spełniać kryteria hemodynamiczne (skurczowe ciśnienie tętnicze ≥90 mmHg oraz rytm zatokowy z częstotliwością akcji serca ≥65 uderzeń/minutę), by spełnić kryteria włączenia do badania i otrzymać lek. 2. Kryteria włączenia zostały dobrane tak, by minimalizować ryzyko interakcji leku ze znanymi substancjami oraz chorobami pacjenta. 3. Monitorowanie ciśnienia tętniczego krwi i częstotliwości akcji serca po zabiegu, pooperacyjny zapis EKG 4. Lek będzie stosowany przez krótki okres, co powinno zmniejszać ryzyko powikłań związanych z jego stosowaniem. 5. Lek będzie podawany wyłącznie podczas hospitalizacji, co zapewni precyzyjną obserwację chorych oraz wiarygodną ocenę częstości występowania działań niepożądanych 1.9 Obserwacja uczestników badania 1.9.1 Hospitalizacja Pacjenci będą obserwowani po zabiegu podczas hospitalizacji (monitorowanie i powtarzana ocena stanu pacjenta, przegląd dokumentacji medycznej, odnotowywanie punktów końcowych). Stężenie troponiny sercowej będzie mierzone pierwszego, drugiego oraz trzeciego dnia po zabiegu. W razie stwierdzenia zwiększonego stężenia troponiny sercowej u pacjenta, personel wdroży standardowe procedury postępowania obejmujące m.in. wykonanie zapisu EKG. W razie konieczności wykonane zostanie badanie echokardiograficzne oraz konsultacja kardiologiczna. 1.9.2 Obserwacja 30-dniowa Personel badawczy skontaktuje się z uczestnikami badania podczas planowej, pooperacyjnej wizyty kontrolnej lub drogą telefoniczną 30 dni po zabiegu. Wówczas zostanie przeprowadzony szczegółowy wywiad celem oceny wystąpienia zdarzeń niepożądanych oraz wystąpienia punktów końcowych. Nieplanowane wizyty mogą odbyć się w razie konieczności wcześniejszego odstawienia badanego leku lub konieczności ponownego włączenia badanego leku. 1.9.3 Obserwacja roczna Personel badania skontaktuje się z uczestnikiem telefonicznie rok po zabiegu. W razie zgłoszenia przez pacjenta zdarzeń niepożądanych lub wystąpienia punktów końcowych, podjęta zostanie próba uzyskania odpowiedniej dokumentacji medycznej. Pacjenci zostaną poinformowani o zakończeniu trwania badania. 1.10 Punkty końcowe 1.10.1 Pierwotny punkt końcowy Uszkodzenie mięśnia sercowego po zabiegu pozasercowym (MINS) definiowane jako dowolny zawał mięśnia sercowego lub dowolne podwyższone stężenie troponiny sercowej będące następstwem niedokrwienia mięśnia sercowego w trakcie lub w ciągu 30 dni po operacji pozasercowej. 1.10.2 Drugorzędowe punkty końcowe Drugorzędowe punkty końcowe w obserwacji 30-dniowej po zabiegu: złożony punkt końcowy obejmujący zgon z przyczyn naczyniowych, MINS niezakończone zgonem, udar mózgu niezakończony zgonem oraz zatrzymanie krążenia niezakończone zgonem; zgon z przyczyny naczyniowej; MINS niespełniające kryteriów zawału mięśnia sercowego zawartych w 4. uniwersalnej definicji zawału mięśnia sercowego (MI); zawał mięśnia sercowego; szczytowe stężenie troponiny sercowej; całkowite stężenie troponiny sercowej; liczba dni, które pacjent przeżył będąc w domu; udar mózgu; zgon z dowolnej przyczyny jakość życia związana ze stanem zdrowia; odwołanie/odłożenie w czasie operacji w dniu zabiegu ze względu na obawy związane z częstością akcji serca; istotne kliniczne migotanie przedsionków; istotna klinicznie bradykardia; istotna klinicznie hipotensja oraz fosfeny. 1.10.3 Trzeciorzędowe punkty końcowe Trzeciorzędowe punkty końcowe w obserwacji: 30-dniowej: zabieg rewaskularyzacji naczyń wieńcowych; rehospitalizacja z przyczyn naczyniowych; ostre uszkodzenie mięśnia sercowego spełniające kryteria zawarte w 4. uniwersalnej definicji zawału mięśnia sercowego; zatrzymanie krążenia niezakończone zgonem; ostra zastoinowa niewydolność serca; zakrzepica żył głębokich/zatorowość płucna; poważne krwawienie zgodnie z definicją Międzynarodowego Towarzystwa Zakrzepicy i Hemostazy (ISTH); krwawienie niezależnie związane ze śmiertelnością po zabiegu pozasercowym; sepsa; ostre uszkodzenie nerek spełniające kryteria KDIGO; ostre uszkodzenie nerek wymagające stosowania dializoterapii; amputacja; liczba dni poza oddziałem intensywnej terapii; czas hospitalizacji; czas pobytu w oddziale intensywnej terapii; destynacja wypisu rocznej: zgon z dowolnej przyczyny; zgon z przyczyny naczyniowej; zawał mięśnia sercowego; zabieg rewaskularyzacji naczyń wieńcowych; zatrzymanie akcji serca niezakończone zgonem; udar mózgu; jakość życia związana ze stanem zdrowia; amputacja; zabieg rewaskularyzacji naczyń wieńcowych; rehospitalizacja z przyczyn naczyniowych; 1.11 Analiza statystyczna Porównanie szans na wystąpienie MINS u pacjentów przyjmujących iwabradynę i placebo zostanie przeprowadzone z wykorzystaniem regresji logistycznej. Wynik zostanie zaprezentowany jako iloraz szans z 95% przedziałem ufności. Dodatkowe informacje na temat analizy statystycznej są dostępne w rozdziale 12. pełnego protokołu badania. Na stronie clinicaltrials.gov opublikowany zostanie szczegółowy Plan Analizy Statystycznej. 1.12 Raportowanie występowania działań niepożądanych oraz poważnych działań niepożądanych Poważne działanie niepożądane (SAE) jest definiowane jako niekorzystne zdarzenie medyczne, które, niezależnie od dawki leku, jest: zagrażające życiu lub wymaga hospitalizacji pacjenta/wydłużenia trwającej hospitalizacji pacjenta lub skutkuje trwałą/znaczącą niepełnosprawnością lub jest wrodzoną anomalią/defektem urodzeniowym lub jest zdarzeniem istotnym medycznie. Badacz musi zapewnić, że wszystkie SAE zaobserwowane przez badacza lub zgłoszone przez uczestnika badania po podpisaniu świadomej zgody zostaną zaraportowane przez eCRF. Wszystkie SAE muszą zostać zgłoszone do Biura Projektu w ciągu 24 godzin od momentu, w którym badacz dowiedział się o ich zaistnieniu. W takiej sytuacji personel badania wypełni SAE CRF w bazie danych. Następnie Biuro Projektu zawiadomi odpowiednie władze w ustalonym wcześniej czasie zgodnie z lokalnymi regulacjami. 1.13 Pozostałe kwestie związane z badaniem 1.13.1 Kwestie etyczne Badanie zostanie przeprowadzone zgodnie z protokołem, Deklaracją Helsińską, zasadami dobrej praktyki klinicznej (GCP) oraz obowiązującymi regulacjami polskiego prawa. Przed rozpoczęciem badania, badacz musi uzyskać pisemną i datowaną zgodę Urzędu Rejestracji Produktów Leczniczych Wyrobów Medycznych i Produktów Biobójczych (URPL) oraz centralnej Komisji Bioetycznej. Po ich uzyskaniu wszyscy główni badacze z uczestniczących ośrodków muszą uzyskać: korzystną opinię odpowiedniej lokalnej Komisji Bioetycznej dot. protokołu badania, formularza zgody pacjenta na udział w badaniu, informacji dla pacjenta, jak również kontrakt pomiędzy ośrodkiem a Biurem Projektu przed rozpoczęciem badania. Zestawienie potencjalnych korzyści i szkód wynikających z przeprowadzenia badania PREVENT-MINS wskazuje na zasadność jego przeprowadzenia. Podwyższona częstotliwość akcji serca jest znanym czynnikiem prognostycznym wystąpienia poważnych powikłań okołooperacyjnych. Iwabradyna jest lekiem o dobrym profilu bezpieczeństwa, który zmniejsza częstotliwość akcji serca bez istotnego wpływu na ciśnienie tętnicze krwi. Biorąc pod uwagę wyniki badań w populacji chorych z przewlekłym zespołem wieńcowym oraz przewlekłą niewydolnością serca, wydaje się, że trwające maksymalnie 7 dni leczenie iwabradyną w okresie okołozabiegowym nie powinno wiązać się z istotnym ryzykiem poważnych działań niepożądanych dla pacjentów. 1.13.2 Zarządzanie danymi Personel badawczy przed rozpoczęciem badania przejdzie szkolenie, by zapewnić spójność procedur badawczych, w tym zbierania danych oraz raportowania kwestii bezpieczeństwa. Personel badania wypełni CRF przez program komputerowy „eCRF.biz”. Dane będą przechowywane na bezpiecznym serwerze administrowanym przez BioStat. dokumentacja źródłowa potwierdzająca informacje raportowane w CRF będzie zbierana w danym ośrodku i udostępniane w celu monitorowania, kontroli Komisji Bioetycznej oraz inspekcji prawnych. Plan zarządzania danymi zostanie przygotowany zgodnie z zasadami dobrych praktyk postępowania z danymi klinicznymi (GCDMP). 1.13.3 Kwestie związane z COVID-19 Pandemia choroby wywołanej przez koronawirusa SARS-CoV-2 2019 (COVID-19) może mieć wpływ na przebieg badania klinicznego ze względu na różne okoliczności, takie jak: izolacja/kwarantanna uczestników badania i personelu ośrodka badawczego; ograniczenia w podróżowaniu /ograniczony dostęp do miejsc publicznych, w tym szpitali; niedobór personelu ośrodka badawczego przydzielonego do konkretnych działań związanych z COVID-19; terminowy dostęp do badanych leków ze względu na ograniczenia logistyczne wynikające z zakłóceń transportu; opóźnienia zabiegów planowych; dostęp obserwatorów i audytorów do ośrodków badawczych. Badanie kliniczne PREVENT-MINS dotyczy pacjentów, którzy będą poddawani zabiegom operacyjnym, w większości w trybie planowym, czyli ich udział w badaniu nie wiąże się z dodatkowym kontaktem z opieką zdrowotną. Obecnie w większości szpitali planowe przyjęcia odbywają się po okazaniu zaświadczenia o szczepieniu lub wykonaniu wymazu w kierunku obecności wirusa SARS-CoV-2. Wizyta kontrolna po 30 dniach będzie w miarę możliwości powiązana z wizytą kontrolną po zabiegu lub odbędzie się w formie telefonicznej, aby również nie narażać pacjentów na dodatkowy kontakt z opieką zdrowotną. Kontrola roczna jest wyłącznie telefoniczna. Wszelkie procedury w badaniu PREVENT-MINS będą się odbywać z zachowaniem zasad bezpieczeństwa epidemiologicznego - badacze będą używać maseczek ochronnych, będą przestrzegać zasad higieny rąk, a pomieszczenia i aparatura będą podlegać stosowanej dezynfekcji. Zdarzenia w czasie trwania badania związane z COVID-19 będą odnotowywane w odpowiedniej dokumentacji badania. "],["ivabradine-for-prevention-of-myocardial-injury-after-noncardiac-surgery.html", "2 Ivabradine for PREVENTion of Myocardial Injury after Noncardiac Surgery 2.1 CLINICAL TRIAL SUMMARY 2.2 INTRODUCTION AND RATIONALE 2.3 PLAN OF INVESTIGATION 2.4 ELIGIBILITY CRITERIA 2.5 RANDOMISATION 2.6 TRIAL INTERVENTIONS 2.7 PLAN TO MINIMIZE RISKS OF, MONITORING FOR, AND APPROACH TO POTENTIAL PROBLEMS 2.8 OTHER MANAGEMENT AT THE DISCRETION OF THE ATTENDING PHYSICIAN 2.9 FOLLOW-UP 2.10 TRIAL OUTCOMES 2.11 ADJUDICATION OF TRIAL OUTCOMES 2.12 DATA ANALYSES 2.13 REPORTING OF ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS 2.14 SUBSTUDIES 2.15 TRIAL MANAGEMENT 2.16 OTHER CONSIDERATIONS 2.17 IMPORTANCE OF PREVENT-MINS TRIAL 2.18 TRIAL CONDUCT DURING THE COVID-19 PANDEMIC 2.19 REFERENCES 2.20 PREVENT-MINS Trial Procedure Schedule 2.21 TRIAL FLOW CHART 2.22 APPENDIX II. PREVENT-MINS Outcome Definitions 2.23 APPENDIX III. PREVENT-MINS Sample Size Calculation", " 2 Ivabradine for PREVENTion of Myocardial Injury after Noncardiac Surgery PREVENT MINS Trial Protocol Version 2.1 March 10, 2022 Sponsor: Jagiellonian University Medical College Principal Investigator: Wojciech Szczeklik, MD, PhD Trial Chair: P.J. Devereaux, MD, PhD 2.1 CLINICAL TRIAL SUMMARY Title: Ivabradine for PREVENTion of Myocardial Injury after Noncardiac Surgery (MINS) - PREVENT-MINS Trial. Study Design: Multicentre, randomised, placebo-controlled trial of ivabradine as add-on therapy to standard medical treatment. Sample size: 2500 patients. Primary Objectives: To determine the effect of perioperative administration of ivabradine in patients with, or at risk of, atherosclerotic disease who are undergoing noncardiac surgery. The primary outcome is myocardial injury after non-cardiac surgery (MINS) defined as any myocardial infarction and any elevated postoperative cardiac troponin judged as resulting from myocardial ischaemia during or within 30 days after noncardiac surgery. Secondary Objectives: To determine the impact of ivabradine on the following outcomes at 30 days after surgery: a composite of vascular death, non-fatal MINS, non-fatal stroke, and non-fatal cardiac arrest; vascular death; MINS not fulfilling the criteria of myocardial infarction; myocardial infarction; peak troponin concentration; area under the curve troponin; days alive and at home; stroke; all-cause mortality; health-related quality of life; cancellation/postponement of surgery on the day of surgery due to HR concerns; clinically important atrial fibrillation; safety outcomes including clinically significant bradycardia, clinically significant hypotension and phosphenes. Tertiary Objectives: To determine the impact of ivabradine on outcomes including:1) at 30 days after surgery: cardiac revascularization; re-hospitalization for vascular reasons; acute myocardial injury according to the Fourth Universal Definition of Myocardial Infarction; non-fatal cardiac arrest; acute congestive heart failure; deep vein thrombosis/pulmonary embolism; major bleeding according to ISTH definition; bleeding independently associated with mortality after noncardiac surgery; sepsis; acute kidney injury fulfilling KDIGO criteria; acute kidney injury requiring dialysis; amputation; days outside the Intensive Care Unit; length of hospital stay; length of ICU stay; discharge destination2) at 1 year after surgery: all-cause mortality; vascular death; myocardial infarction; non-fatal cardiac arrest; stroke; health-related quality of life; amputation; cardiac revascularization; re-hospitalization for vascular reasons. Inclusion criteria: Patients are eligible if they fulfil all of the following criteria: 1. ≥45 years of age; 2. Expected to require at least an overnight hospital admission after noncardiac surgery; 3. Provide written informed consent to participate in the PREVENT-MINS Trial AND fulfil ≥1 of the following 5 criteria (A-E): A. Current or prior history of coronary artery disease; B. Current or prior history of peripheral arterial disease; C. History of stroke; D. Undergoing major vascular surgery OR E. Any 3 of the following 9 risk criteria: i.) Undergoing major surgery (i.e. intraperitoneal, intrathoracic, retroperitoneal, major orthopedic); ii. History of congestive heart failure; iii. History of a transient ischaemic attack; iv. History of diabetes; v. Age ≥70 years; vi. History of hypertension; vii. Serum creatinine ≥175 μmol/L (≥2.0 mg/dl); viii. History of smoking within 2 years of surgery; ix. Undergoing emergent/urgent surgery. Treatment regimen: Patients fulfilling hemodynamic requirements will receive 5mg of oral ivabradine or matching placebo as an add on to the standard treatment twice daily starting ≥1 hour before surgery and continued for up to seven days after surgery. Follow-up: 30 days and 1 year. 2.2 INTRODUCTION AND RATIONALE More than 230 million major noncardiac surgeries are performed worldwide each year and this number is increasing (1-3). The Vascular events In noncardiac Surgery patIents cOhort evaluatioN (VISION) prospective cohort study - which enrolled a representative sample of 40,000 adults ≥45 years from 28 centres in 14 countries - demonstrated that 1.8% of patients having inpatient noncardiac surgery died within 30 days of the procedure (4). In the VISION Study, ischaemic myocardial injury after noncardiac surgery accounted for 13% of all postoperative deaths (5). Patients with myocardial injury after noncardiac surgery have a poor long-term prognosis, with 1 in 7 patients suffering a major vascular complication at a mean time of 16 months of follow-up (6). There is evidence that perioperative tachycardia is associated with an increased risk of myocardial ischaemia and death after noncardiac surgery (7-10). Randomised controlled trials have shown that beta-blockers reduce heart rate and decrease the risk of perioperative myocardial ischaemia at the expense of increasing the risk of clinically important hypotension, stroke, and mortality (11). Ivabradine is a pure heart rate lowering drug which in contrast to beta-blockers decreases myocardial oxygen demand without affecting blood pressure or ventricular contractility (12). Ivabradine has proven efficacy and safety in patients at risk of major cardiovascular complications in the non-surgical setting. The most common side-effects associated with the administration of ivabradine include bradycardia and phosphenes, which are a transiently enhanced brightness in a limited area of the visual field. Preliminary data on the perioperative use of ivabradine are promising, yet inconclusive (13, 14). We will conduct a multicentre randomised controlled trial (i.e. PREVENT-MINS) of ivabradine versus placebo in patients with, or at risk of, atherosclerotic disease who are undergoing noncardiac surgery. 2.2.1 Principal research question PREVENT-MINS will address the following question: is ivabradine superior to placebo for the prevention of myocardial injury after noncardiac surgery (MINS) in patients with or at risk of atherosclerotic disease having noncardiac surgery? 2.2.2 The need for PREVENT-MINS trial 2.2.2.1 Rationale for evaluating an intervention that can reduce heart rate in the perioperative period Multiple studies have shown that perioperative tachycardia is associated with an increased risk of cardiac complications and death (7-9, 15-19). Tachycardia causes myocardial oxygen supply-demand mismatch by reducing the duration of diastole and may lead to rupture of unstable atherosclerotic plaques with subsequent occlusion of coronary arteries (15, 20, 21). The VISION study demonstrated that myocardial injury after noncardiac surgery (MINS) defined as a troponin elevation within 30 days after noncardiac surgery judged to be due to ischaemia is associated with poor prognosis regardless of the presence of ischaemic features (i.e. ischemic symptoms or ECG findings) (4). Periprocedural myocardial injury has been recognized in the Fourth Universal Definition of Myocardial Infarction as a distinct clinical diagnosis (22). Both preoperative and intraoperative tachycardia have been shown to be associated with an increased risk of MINS, with a linear increase in the risk of MINS with increasing values of heart rate (7, 8). There is evidence that rigorous heart rate control may prevent perioperative myocardial infarctions (23). Results of two large randomised controlled trials which evaluated the efficacy of metoprolol (POISE) and clonidine (POISE-2) in preventing major cardiac complications after noncardiac surgery suggest that substantial heart rate reduction is a promising cardioprotective strategy provided that it does not result in hypotension (11, 24). Ivabradine is a selective heart rate lowering agent that both reduces myocardial oxygen demand and improves oxygen supply without significant adverse haemodynamic effects (25). Small observational and interventional studies provide encouraging but not definitive evidence on the utility of ivabradine in surgical settings (13, 14, 26). Therefore, the efficacy and safety of ivabradine in noncardiac surgery has not yet been established. 2.2.2.2 Evidence regarding perioperative heart rate and cardiovascular events and mortality Association between preoperative heart rate and perioperative complications has been evaluated in several studies. Data from the largest report, the VISION study, suggested a significant association between increased preoperative heart rate (&gt;96 beats/min) and incidence of MINS (OR 1.48, 95% CI 1.23–1.77), MI (OR 1.71, 95%CI 1.34–2.18) and mortality (OR 3.16, 95%CI 2.45–4.07). At the same time low preoperative heart rate (&lt;60 beats/min) was found to be related to decreased mortality (OR 0.50, 95%CI 0.29–0.88). Data from the POISE trial also demonstrated that every 10-beats/min increase in pre-randomisation heart rate was associated with a 31% relative increase in the odds of perioperative MI (adjusted OR, 1.31; 95% CI, 1.12-1.52). 2.2.2.3 Experimental efficacy and safety evidence of ivabradine in noncardiac surgery Ivabradine acts on the mixed Na+/K+ inward ion current called If, which is one of the most important ionic currents involved in the pacemaker activity of the sinoatrial node. Ivabradine selectively inhibits the pacemaker If current in a dose-dependent manner, thus reducing heart rate and increasing time for blood to flow to the myocardium. In contrast to other heart rate reducing medications (e.g. beta-blockers and calcium channel blockers), ivabradine does not significantly decrease blood pressure. Hellenbart and colleagues performed a scoping review of the literature and identified two small randomised controlled trials evaluating preoperative administration of ivabradine (14, 27, 28). We found two additional experimental studies which used ivabradine to attenuate haemodynamic response to laryngoscopy and endotracheal intubation (26, 29). Periprocedural heart rate was lower in the group of patients receiving ivabradine than in the control group in all four trials. One study showed that 5 mg of ivabradine administered in the evening before surgery and repeated 1 hour before the induction of anaesthesia provided better control of the heart rate than 10 mg of propranolol (14). Mathur and colleagues performed a randomised controlled trial in patients having nasal and laryngeal surgeries and found that 5 mg of ivabradine lowers the heart rate and blood pressure to a lesser degree than 50 mg of metoprolol tartrate (29). Out of the total of 105 patients randomly allocated to receive ivabradine shortly before surgery, no patient experienced bradycardia or hypotension. The majority of participants enrolled in previous trials were healthy adults. None of the identified experimental studies assessed the incidence of major cardiac complications after noncardiac surgery. The only study evaluating the role of ivabradine administered both before and after surgery in preventing cardiac complications in patients at high risk of perioperative myocardial ischaemia was a non-randomised one and had few events available for analysis (13). In summary, results of small trials performed in relatively healthy patients suggest that a 5 mg dose of ivabradine initiated shortly before surgery lowers heart rate in the perioperative period without causing hypotension. There is insufficient evidence to assess the risk and benefit profile of ivabradine in patients with or at risk of atherosclerotic disease scheduled for noncardiac surgery. 2.2.2.4 Experimental evidence regarding the use of ivabradine in other clinical settings Borer and colleagues randomly assigned 360 patients with a ≥3-month history of chronic coronary syndrome (CCS) to receive ivabradine (2.5 mg, 5 mg or 10mg twice a day) or placebo for 2 weeks and later switched all participants to 10 mg of ivabradine twice a day in an open label extension of the trial followed by a 1-week randomised withdrawal of the study drug (30). In a per-protocol analysis of 257 patients, the time to 1-mm-ST-segment depression at through of drug activity at day 14 increased by 9.0 (63.6) seconds (s) with placebo and 32.0 (74.3), 44.1 (80.1), and 46.2 (78.2) s with ivabradine 2.5 mg, 5 mg, and 10 mg respectively, with the difference being statistically significant in case of the 5 mg and 10 mg dose. Time to limiting angina was significantly higher in patients receiving the 10 mg dose compared to placebo (69.4 [74.8] s vs 24.7 [64.2] s) and numerically higher with lower doses of ivabradine than with placebo. Three patients withdrew from the study due to transient visual symptoms, which occurred in 1 patient in each of the lower dosage groups and 13 patients receiving 10 mg of ivabradine twice a day. No cardiac adverse events were observed after withdrawal of the study drug, which suggests that stopping treatment with ivabradine is safe and does not result in rebound phenomena. The INITIATIVE trial randomised 939 patients with CCS to receive ivabradine 5 mg or atenolol 50 mg, up titrated to (7.5 or 10 mg) and (100 mg), respectively after 4 weeks (31). The total exercise duration after one month of treatment was similar in both groups, with a 6.7 s (95% CI from -7.4 to 20.8) difference in favour of ivabradine. Ivabradine induced a similar or greater improvement in exercise capacity than atenolol for a comparatively smaller reduction in the heart rate and rate pressure product at peak exercise. Ivabradine was non-inferior to atenolol in terms of all studied endpoints regardless of the dose and reduced the number of angina attacks by two-thirds. Ivabradine was well tolerated, with only 2 out of 315 patients withdrawing from the treatment due to transient visual symptoms and 7 out of 315 patients experiencing sinus bradycardia in the group allocated to receive 7.5 mg dose of ivabradine. Ruzyllo and colleagues compared the antianginal efficacy and safety of ivabradine and amlodipine in a randomised trial of 1195 patients with CCS (32). The total exercise duration at 3 months was improved by 27.6 (91.7), 21.7 (94.5), and 31.2 (92.0) seconds with ivabradine 7.5 mg, 10 mg, and amlodipine 10 mg respectively. Ivabradine was non-inferior to amlodipine in terms of time to angina onset and 1 mm ST-segment depression. Ivabradine was superior to amlodipine for reducing myocardial workload and significantly decreased heart rate at rest as well as at peak exercise by 11-13 and 12-15 beats per minute respectively. Less than 1% of the patients withdrew from treatment due to visual symptoms. Sinus bradycardia was the cause of withdrawal of treatment in only 0.4% of the patients. In the ASSOCIATE trial (n=889), the addition of ivabradine 5 mg (later titrated to 7.5 mg) to 50 mg of atenolol in patients with CCS resulted in an increase in the total exercise time of 24.3 s (65.3) compared to 7.7 s (63.8) with placebo (33). Ivabradine was superior to placebo for all of the prespecified exercise test criteria, reduced the heart rate as well as rate-pressure product at the peak of exercise, and ivabradine was well tolerated with only 1.1% of patients allocated to the intervention arm withdrawing due to sinus bradycardia. The BEAUTIFUL (If Inhibitor Ivabradine in Patients With Coronary Artery Disease and Left Ventricular Dysfunction) trial enrolled 10 917 patients with CCS and left-ventricular systolic dysfunction (ejection fraction &lt;40%) to evaluate the impact of ivabradine (5 mg, with the intention of increasing to the target dose of 7.5 mg twice a day) on cardiac outcomes (34). The trial did not demonstrate evidence of benefit with ivabradine compared to placebo in terms of the primary composite endpoint of cardiovascular death, admission to hospital for acute myocardial infarction, and admission to hospital for new onset or worsening heart failure, with a hazard ratio of 1.00 (95% CI 0.91-1.1). In a prespecified subgroup of patients with heart rate of 70 beats per minute or greater, the hazard ratio for the primary outcome was equal to 0.91 (95% CI 0.81-1.04) when comparing ivabradine to placebo. Ivabradine reduced admissions to hospital for fatal and non-fatal myocardial infarction (hazard ratio of 0.64, 95% CI 0.49-0.84) and coronary revascularization (hazard ratio 0.70, 95% CI 0.52-0.93) in this subgroup, despite the fact that 84% of patients with heart rate ≥70 beats per minute were treated with beta-blockers. The mean difference between the placebo and ivabradine groups in change from baseline resting heart rate at 6 months was equal to 7.2 beats per minute (95% CI 6.8–7.5). Bradycardia was more common in the ivabradine group than in the placebo group (13% vs 2%), but only 146 (21%) patients receiving ivabradine who withdrew from treatment due to bradycardia were symptomatic. Bradycardia was less common in the subgroup of patients with a baseline heart rate of ≥70 beats per minute in both the ivabradine and placebo group (reason for discontinuation of treatment in 6% vs 1% of patients respectively). Visual symptoms such as phosphenes were transient and led to withdrawal from treatment in 37 (0.3%) of patients. The authors concluded that ivabradine is safe in patients with coronary artery disease and reduced ejection fraction, and that it can be safely combined with beta-blockers. The SIGNIFY trial randomised 19 102 patients who had CCS with a heart rate ≥70 beats per minute to receive ivabradine at a starting dose of 7.5 mg twice daily (except for patients ≥75 years old, who received a reduced dose of 5.0 mg twice a day) or matching placebo on top of guideline-based medical treatment (35). After three months of treatment, the mean heart rate was reduced to 60.7 (9.0) and 70.6 (10.1) beats per minute in the ivabradine and placebo groups respectively. The trial did not provide sufficient evidence to reject the null hypothesis of no difference between ivabradine and placebo in terms of the primary composite outcome of death from cardiovascular causes or nonfatal myocardial infarction with a hazard ratio of 1.08 (95% CI 0.96-1.20). Unexpectedly, ivabradine was associated with an increase in the incidence of the primary end point in the subgroup of patients who had angina classified as Canadian Cardiovascular Society class 2 or higher with a hazard ratio of 1.18 (95% CI 1.03-1.35). Among patients without angina or those classified as Canadian Cardiovascular Society class 1, the hazard ratio for the primary outcome when comparing ivabradine to placebo was 0.89 (95% CI 0.74-1.08). In SIGNIFY, drug withdrawal was more common in the ivabradine group than in the placebo group (13.2% vs 7.4%), with symptomatic and asymptomatic bradycardia leading to withdrawal of treatment in 1.9% and 2.1% of patients receiving ivabradine and 0.3% and 0.2% of patients in the placebo group respectively. The overall incidence of symptomatic and asymptomatic bradycardia in the ivabradine group was 7.9% and 11.0%, respectively, compared to 1.2% and 1.3%, respectively, in the placebo group. Phosphenes led to study-drug withdrawal in 0.6% of patients receiving ivabradine and 0.1% of those receiving placebo. The authors indicated that the relatively high incidence of bradycardia in SIGNIFY was due to the higher than recommended initiation and maintenance doses of ivabradine. A systematic review by Ferrari and colleagues which identified 13 blinded randomised trials with a sample size of at least 100 patients comparing different anti-anginal drugs in patients with CCS concluded that no anti-anginal drug is superior to another, with equivalence demonstrated only between beta-blockers, calcium channel blockers and ivabradine (36). The authors deemed pooling of the trials’ results inappropriate due to methodological differences. One systematic review summarising safety outcomes in the three largest ivabradine trials conducted to date showed that phosphenes occurred in 601/12,771 (4.7%) of patients treated with ivabradine and 69/12,804 (0.5%) patients receiving placebo (37). Symptomatic bradycardia was reported in 907/12,771 (7.1%) patients from the ivabradine groups compared to 142/12,804 (1.1%) in the placebo groups. Atrial fibrillation was more common with ivabradine than with placebo (814/12771 [6.3%] vs 613/12804 [4.7%]) with an odds ratio equal to 1.35 (95% CI 1.21–1.51). The increase in the risk of atrial fibrillation due to ivabradine, though smaller than previously estimated, was confirmed in yet another systematic review which included over 40,000 participants (5.34% vs 4.56%) (38). The SHIFT trial randomised 6558 patients with symptomatic heart failure and a left-ventricular ejection fraction of 35% or lower, in sinus rhythm, with a heart rate of ≥70 beats per minute who had been hospitalized for heart failure within the previous 12 months to receive ivabradine (5 mg twice daily starting dose with the possibility of later up titration to 7.5 mg twice daily) or placebo on top of optimal medical therapy (39). Treatment with ivabradine was associated with an average reduction in heart rate of 15 beats per minute from a baseline heart rate of 80 beats per minute. The primary endpoint (i.e. a composite of cardiovascular death or hospital admission for worsening heart failure) occurred in 793 (24%) patients in the ivabradine group and 937 (29%) of those taking placebo, resulting in a hazard ratio of 0.82 (95% CI 0.75–0.90). Both individual components of the primary outcome were significantly less common in patients receiving ivabradine compared to placebo. In a post-hoc analysis, ivabradine reduced the incidence of cardiovascular death or hospitalisation for worsening heart failure regardless of the presence of angina at baseline (40). Serious adverse events were less common in the ivabradine group than in the placebo group, but the incidence of symptomatic bradycardia (5% vs 1%) and phosphenes (3% vs 1%) was higher with ivabradine than with placebo. Data from the SHIFT trial suggest that ivabradine is more effective in the subgroup of patients with a baseline heart rate ≥75 beats per minute, the threshold at which ivabradine was registered for use in patients with chronic heart failure New York Heart Association class II to IV with systolic dysfunction by the European Medicines Agency (41). A pooled analysis of individual patient data from the SHIFT and BEAUTIFUL trials demonstrated that ivabradine reduces the risk of major outcomes in a broad population of patients with left ventricular systolic dysfunction and a heart rate ≥70 beats per minute regardless of the primary clinical presentation (i.e. coronary artery disease or heart failure), severity of disease (i.e. New York Heart Association class or ejection fraction), and background dose of beta-blockers (42). The hazard ratio for cardiovascular mortality, hospital admission for heart failure or hospital admission for myocardial infarction in 11,897 patients randomised to ivabradine or placebo in either of the two trials was equal to 0.85 (95% CI 0.79-0.91). The use of ivabradine has also been actively investigated in other populations (e.g. patients with conduction abnormalities or left ventricular dysfunction undergoing cardiac surgery, critically ill patients, patients with mitral stenosis), with many trials conducted on relatively small groups of patients and yielding inconclusive results. We summarised these additional studies in APPENDIX I. Based on the available evidence, the European Society of Cardiology currently recommends ivabradine as a second-line (class IIa recommendation) or first line (in combination with a beta-blocker or a calcium channel blocker; class IIb recommendation) anti-ischaemic treatment in patients with CCS who are in sinus rhythm (43). Ivabradine has received a class IIa recommendation to reduce the risk of hospitalization for worsening heart failure or cardiovascular death in symptomatic patients with left ventricular ejection fraction ≤35%, in sinus rhythm and a resting heart rate ≥70 beats per minute, despite optimal medical treatment (including an evidence-based dose of a beta-blocker or as a substitute for a beta-blocker in patients who are unable to tolerate or have contra-indications for beta-blockers) (44). In patients with CCS and symptomatic heart failure (New York Heart Association class II-IV) with systolic dysfunction and a resting heart rate ≥70 bpm, ivabradine has a class IIa recommendation as an add-on anti-anginal drug on top of a beta-blocker or as a substitution for a beta-blocker in patients who do not tolerate beta-blockers. Evidence summary Ivabradine has been used in the European Union since 2005 and safety data have been established from trials enrolling thousands of participants in the non-operative setting. Two specific adverse events are known to be related to the pharmacological action of ivabradine: sinus bradycardia and transient visual disturbances known as phosphenes, which occur in approximately 7% (symptomatic cases) and 5% of patients treated with ivabradine in the largest clinical trials conducted to date respectively. Phosphenes are benign and transient phenomena, which rarely lead to withdrawal of treatment and bradycardia is less common with higher baseline heart rates. Ivabradine is associated with an approximately 1% absolute increase in the risk of detected atrial fibrillation according to a recent meta-analysis. Treatment with ivabradine, either alone or in combination with beta-blockers, is currently considered both effective and safe in patients with CCS and heart failure. Results of randomised controlled trials suggest that ivabradine could prevent perioperative myocardial ischaemia on par with beta-blockers with less side effects, particularly hypotension. A meta-analysis of randomised trials in patients undergoing noncardiac surgery showed a substantial reduction in the incidence of perioperative myocardial infarction with beta-blockers, but this benefit was considered to be outweighed by the increased risk of clinically relevant hypotension, stroke, and death resulting from perioperative beta-blockade. Therefore, we need to establish the efficacy of ivabradine in patients having noncardiac surgery. 2.2.2.5 Rationale for PREVENT-MINS ivabradine dose Data regarding the influence of ivabradine on cardiac complications after surgery in patients at high risk of perioperative myocardial ischaemia are inconclusive (13). Results of small trials performed in relatively healthy patients suggest that a 5 mg dose of ivabradine initiated shortly before surgery lowers heart rate in the perioperative period without causing hypotension (14, 29), but does not provide sufficient evidence to assess the risk and benefit profile of different doses of ivabradine in patients with or at risk of atherosclerotic disease scheduled for noncardiac surgery. According to results of two large trials evaluating ivabradine in non-operative clinical settings, the use of ivabradine 5-7.5 mg twice daily increased the incidence of bradycardia compared to placebo, but most of these events were asymptomatic (34, 39). The relatively high incidence of bradycardia in the SIGNIFY trial was attributed to the higher than recommended initiation and maintenance doses of ivabradine. Based on these data, in the PREVENT-MINS trial we will use a 5mg dose of Ivabradine twice daily, initiated ≥1 hour before surgery and continued for up to 7 days after surgery. 2.2.2.6 Effect of heart rate reducing medications on perioperative cardiovascular events and mortality Several RCTs assessed the impact of perioperative administration of beta blockers, among which the largest study (POISE trial) showed that perioperative administration of metoprolol decreased the incidence of myocardial infarction (HR 0.84, 95% CI 0.70 to 0.99) but simultaneously increased mortality (HR 1.33, 1.03 to 1.74) and rate of stroke (HR 2.17, 95% CI 1.26 to 3.74). Adverse events were predominantly attributed to the increased incidence of clinically important hypotension. Meta-analysis of nine RCTs of perioperative beta-blockers administration, encompassing 10 529 patients, showed a reduction of nonfatal MI (RR 0.73, 95% CI 0.61 to 0.88) but an increased 30-day mortality (RR 1.27, 95% CI 1.01 to 1.60) as well as a higher incidence of stroke (RR 1.73, 95% CI 1.00 to 2.99) and hypotension (RR 1.51, 95%CI 1.37 to 1.67). These results were mainly driven by the POISE trial, but the results are consistent even when the POISE trial was not included. The potential benefit associated with perioperative heart rate decrease was also an element of the rationale for the POISE-2 trial in which a different HR-reducing medication, clonidine, was administered perioperatively to reduce the incidence of perioperative cardiovascular complications. Clonidine mechanism of action is multidirectional - it not only lowers blood pressure by stimulating presynaptic α2-receptors and imidazoline-1 receptors in the brain, but also reduces heart rate, most probably by its action through the vagus nerve. POISE-2 trial failed to show a difference between clonidine and placebo groups in terms of the primary outcome (i.e. a composite of death and non-fatal myocardial infarction) with a HR of 1.08 (95% CI 0.93 to 1.26; P=0.29). Similar to the first POISE trial, there was an increase in the incidence of clinically important hypotension in the intervention arm compared to placebo (HR 1.32; 95% CI, 1.24 to 1.40). Moreover, patients receiving clonidine more often suffered nonfatal cardiac arrest (HR 3.20; 95% CI, 1.17 to 8.73). The authors reported that the less pronounced cardioprotective effect of clonidine compared to metoprolol may have been due to the less pronounced impact on heart rate with clonidine; clinically significant bradycardia had a HR of 2.74 (95% CI, 2.19–3.43) in POISE-1, whereas it was only 1.49 (95% CI,1.32–1.69) in POISE-2. The entire body of evidence suggests that an ideal drug in prevention of cardiovascular complications after surgery would be one that slows down the heart rate and does not cause substantial hypotension, hence ivabradine is a promising intervention to study in this setting. 2.2.2.7 The feasibility of PREVENT-MINS Our group has collectively participated in several large perioperative studies including VISION, VISION-CTA, MANAGE, HIP ATTACK, POISE 3 and OPTIMIZE II. These studies enabled us to establish the incidence of MINS in the Polish population of patients undergoing surgery (with active troponin screening of more than 2000 patients), to evaluate the population at risk (information about comorbidities, tachycardia, hypotension during surgery etc.), and to establish a broad network of cooperating centres with experience in clinical trials. The study was designed to stay in line with the real-life scenario of perioperative care. The drug/placebo will be administered orally over a relatively short period of time during hospitalisation, which will increase compliance and safety. 2.2.2.8 Summary of why PREVENT-MINS is needed now Perioperative tachycardia is associated with an increased risk of cardiac complications and death within 30-days after surgery. Data from randomised trials suggests that reducing patients’ heart rate in the perioperative period prevents myocardial ischaemia. Preliminary evidence suggests that ivabradine is as potent as beta-blockers in preventing myocardial ischaemia and has a more favourable safety profile than beta-blockers concerning the risk of hypotension and stroke in the perioperative period. There is a need for an adequately powered trial to establish the efficacy of ivabradine in preventing myocardial injury after noncardiac surgery and to guide clinical practice in a population of patients with or at risk of atherosclerotic disease undergoing noncardiac surgery. 2.3 PLAN OF INVESTIGATION 2.3.1 Trial objectives 2.3.1.1 Primary objective The study aims to determine whether perioperative administration of ivabradine is superior to placebo for the occurrence of myocardial injury after noncardiac surgery (MINS) within 30 days after randomisation in patients with or at risk of atherosclerotic disease having noncardiac surgery. 2.3.1.2 Secondary and tertiary objectives To determine the impact of ivabradine vs. placebo on the secondary and tertiary outcomes listed in the TRIAL OUTCOMES section. 2.3.2 Trial design The PREVENT-MINS trial is a multicentre RCT of 2500 patients with or at risk of cardiovascular disease randomised to receive either oral ivabradine or placebo in the perioperative period. Patients, health care providers, data collectors, outcome adjudicators, and investigators will all be blinded to patients’ allocation to either arm of the trial. The PREVENT-MINS trial will use a parallel-group design with an equal allocation ratio (see Trial Flow Chart). 2.3.3 Sample size Pooled data from the VISION prospective cohort study that employed active high-sensitivity troponin screening during the first 3 days after surgery and other prospective observational studies using routine troponin measurement indicate that 18% of the control group in the PREVENT-MINS trial will suffer the primary outcome within 30 days (45). Based on results of a meta-analysis that included data from the POISE trial and several RCTs that concluded that ivabradine is likely to exert similar anti-ischaemic effects as beta-blockers, we estimate that 13.5% of the patients in the experimental group will suffer MINS (11). Based on a group sequential design with 2 interim analyses conducted when 50% and 75% outcomes were collected, enrolling 2500 patients will allow us to detect a 25% relative risk reduction with 86.4% power with the overall two-sided type I error rate of α=0.05 guaranteed by using the Lan-DeMets (O’Brien-Fleming) alpha spending function (46). 2.4 ELIGIBILITY CRITERIA 2.4.1 Inclusion criteria Patients are eligible for the study if they fulfil the following criteria for inclusion: Undergoing noncardiac surgery; ≥45 years of age; Expected to require at least an overnight hospital stay after surgery; Written informed consent to participate in the PREVENT-MINS Trial provided, AND Fulfil ≥1 of the following 5 criteria (A-E): A. Current or prior history of coronary artery disease as defined by any one of the following 7 criteria: History of angina; History of acute coronary syndrome; History of a segmental cardiac wall motion abnormality on echocardiography or a segmental fixed defect on radionuclide imaging; History of a positive radionuclide exercise, echocardiographic exercise, or pharmacological cardiovascular stress test demonstrating cardiac ischaemia; History of a coronary angiographic or CT coronary angiographic evidence of atherosclerotic stenosis ≥50% of the diameter of any coronary artery; ECG with pathological Q waves in at least two contiguous leads; OR Previous coronary artery revascularization, (i.e. percutaneous coronary intervention [PCI] or coronary artery bypass graft surgery [CABG]); B. Peripheral arterial disease as defined by a physician diagnosis of a current, or prior history of any of the following 4 criteria: Intermittent claudication; Vascular surgery OR percutaneous transluminal angioplasty (PTA) for atherosclerotic disease; An ankle/brachial systolic blood pressure ratio &lt;0.90 in either leg at rest; OR Angiographic, CT angiographic or doppler findings demonstrating &gt;70% stenosis in a noncardiac artery; C. History of stroke as defined by any one of the following 2 criteria A physician diagnosis of stroke; OR CT or MRI evidence of a prior stroke; D. Undergoing major vascular surgery defined as all vascular surgeries (including any above foot amputation) with the exception of arteriovenous shunt, vein stripping procedures (varicose vein surgery), carotid endarterectomies, endovascular abdominal aortic aneurysm repair (EVAR); OR E. Any 3 of 9 risk criteria: Undergoing major surgery defined as: intraperitoneal, intrathoracic, retroperitoneal, or major orthopaedic; History of congestive heart failure defined as a physician diagnosis of a current or prior episode of congestive heart failure OR prior radiographic evidence of vascular redistribution, interstitial pulmonary edema, or frank alveolar pulmonary oedema; History of a transient ischaemic attack; Diabetes diagnosis and currently taking hypoglycemic agent; Age ≥70 years; History of hypertension; Serum creatinine &gt;175 μmol/L (&gt;2.0 mg/dl) based on the most recent values before randomisation; History of smoking within 2 years of surgery; and Undergoing emergent/urgent surgery, defined as surgery that a surgeon schedules to go to the operating room within 48 hours from an acute presentation to the hospital. 2.4.2 Exclusion criteria Patients with any of the following criteria will not be included in the study: Conduction abnormalities: Non-sinus rhythm on ECG; Sinoatrial or AV (2nd and 3d degree) blocks; Sick sinus syndrome; Long QT syndrome; Pacemaker dependent; Transplanted heart (or on waiting list); Use of a selected class I or III antiarrhythmic drug (quinidine, disopyramide, sotalol, ibutilide, amiodarone) or diltiazem/verapamil; Resting heart rate &lt;65 beats per minute on the day of surgery; Systolic blood pressure &lt;90 mmHg on the day of surgery; Acute decompensated heart failure, cardiogenic shock, acute myocarditis; Acute coronary syndrome within 2 months before surgery; Stroke or transient cerebral ischaemia within 1 month before surgery; Known severe liver or kidney disease (MDRD creatinine clearance &lt;15 mL/min); Inability to tolerate oral intake; Recent use of ivabradine (&lt;1 month); Known allergy or hypersensitivity to ivabradine; Low-risk surgical procedure based on individual physician’s judgment Investigator considers the patient unreliable regarding requirement for study compliance; Women of childbearing potential who are not taking effective contraception, pregnant or breast-feeding; Previously enrolled in the PREVENT-MINS trial. PATIENT RECRUITMENT AND INFORMED CONSENT PREVENT-MINS Trial will enrol patients from more than 20 centres located in Poland. In most centres, study personnel will screen the patient list in the preoperative assessment clinic to identify eligible patients. Study personnel will use a variety of screening approaches to capture patients who do not attend the preoperative assessment clinic, including screening the daily surgical list in the operating room, patients on surgical wards and ICUs, and patients in the preoperative holding area. At each centre, the services of anaesthesia, surgery, and medicine will be asked to notify the study personnel regarding all surgical admissions through the emergency department and ward patients requiring surgery. Study personnel will approach all eligible patients to obtain informed consent before surgery. Whenever possible, patients will be approached in preoperative clinics to inform them about the trial. Patients who were not identified or approached in the preoperative clinic will be contacted before surgery to discuss the trial and their potential participation. 2.5 RANDOMISATION Randomisation will be performed before surgery after a patient is deemed eligible and written informed consent is obtained. Study personnel will randomise patients via an Interactive Web Randomisation System (IWRS). The computerized randomisation process will use random permuted blocks of sizes 4 or 6 and stratification by centre. Study personnel will not know the block size. Patients will be randomised to receive study drug or matching placebo according to a 1:1 ratio. IWRS will be available 24h a day and will ensure full anonymity and security of the data. 2.6 TRIAL INTERVENTIONS 2.6.1 Ivabradine or placebo Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a HR ≥65 bpm) will receive 5mg of oral ivabradine or matching placebo as an add on to the standard treatment at least 1 hour before surgery and the first postoperative dose in the evening or in the morning post-op, at least 12 hours after the preoperative dose provided that HR is ≥65bpm with systolic blood pressure ≥90 mm Hg. Starting on the day after surgery, patients will receive 5mg oral ivabradine or matching placebo twice a day (BID). The administration of the study drug will be stopped after the final dose (i.e. postoperative day 7) or at discharge from the hospital. If the patient develops atrial fibrillation or atrial flutter, the study drug will be held until the patient returns to sinus rhythm. Placebo tablets will have similar appearance as the active drug administered to participants in the intervention group (ivabradine 5mg). Patients, treating physicians, healthcare providers, data collectors, study investigators and statisticians will be blind to treatment allocation. Safety aspects of the intervention: We established safety parameters to hold the drug (e.g. bradycardia, systolic blood pressure &lt;90 mm Hg, onset of atrial fibrillation). Patients with known sensitivity to ivabradine and those deemed to be at an increased risk of adverse events from the study drug (e.g. patients treated with verapamil/diltiazem) based on existing data and statements of regulatory bodies will be excluded from the trial. Investigators and other members of the treatment team will not break the treatment code unless it is absolutely necessary to ascertain the type of treatment received (ivabradine or placebo) by a given patient in order to choose between crucial therapeutic options (please see emergency unblinding section). None of the Project Office nor Steering Committee members will have access to the list of treatments allocated to patients, except the authorised persons of the data management committee (DMC), who will be responsible for supervising all safety aspects of the study. The unblinded documentation will remain confidential and will not be made available to anyone outside the DMC. Preparation and shipment of the study drug/placebo: Both active drug and placebo will be manufactured and packaged at the same pharmaceutical company according to Good Pharmacological Practice rules. Placebo tablets will be manufactured by pharmaceutical company with drug production facilities located in Poland and will meet all standards of study placebo. 2.7 PLAN TO MINIMIZE RISKS OF, MONITORING FOR, AND APPROACH TO POTENTIAL PROBLEMS 2.7.1 Minimising potential risks associated with ivabradine administration 2.7.1.1 Minimising side effects of ivabradine We have incorporated design features into PREVENT-MINS trial to minimize ivabradine side effects risks. First, we will require patients to have SBP ≥90mmHg with a preoperative heart rate of ≥65 beats per minute (bpm) to be eligible for the trial and to receive the study drug. Second, the exclusion criteria in the study were carefully designed to minimize drug interactions with known substances and patients’ conditions. Furthermore, the study drug will only be used for up to 7 days after surgery, which in comparison to other studies in non-surgical settings is a very short period, and the amount of possible ivabradine complications should be relatively smaller. Ivabradine will be administered during hospitalization which will enable careful observation and side effects detection. 2.7.1.2 Minimising significant perioperative bradycardia Perioperative bradycardia can occur for many reasons. It is a known complication during general anaesthesia, as a side effect of inhaled anaesthetics, opioids or agents used to reverse effects of nondepolarizing neuromuscular blocking agents (acetylcholinesterase inhibitors, sugammadex). It can be triggered by surgical intervention. Bradycardia can also occur during neuraxial blockade, when high thoracic level is involved. Fortunately, in most cases bradycardia is transient and resolves spontaneously or after administration of an anticholinergic agent (e.g. atropine) without any further complications. Patients receiving medications that slow the heart rate are at higher risk of developing bradycardia. We will exclude patients receiving nondihydropyridine calcium channel blockers and class I or III antiarrhythmic drugs from the trial to minimize the risk of serious bradyarrhythmias. We will encourage physicians to closely monitor patients, especially ones on beta-blockers, participating in the trial. In case of bradycardia detection, we recommend general management according to the site’s local guidelines. The decision regarding withholding or discontinuing the oral study drug will rest with the attending physician. They will be encouraged to continue the oral study drug unless the patient has clinically important bradycardia or other side effects (e.g. hypotension). If so, physicians may temporarily interrupt or permanently discontinue the study drug. 2.8 OTHER MANAGEMENT AT THE DISCRETION OF THE ATTENDING PHYSICIAN 2.8.1 Perioperative management of patients with other indications for heart rate reducing drugs After hospital admission, patients will be randomly allocated to the treatment strategy: ivabradine or placebo. Administration of all medications that are not contraindicated to be used together with ivabradine is permitted during the study. Patients selected for the study should receive optimal medical therapy appropriate to their cardiovascular condition including all heart rate reducing drugs except nondihydropyridine calcium channel blockers and class I or III antiarrhythmic drugs. Patients unable to tolerate beta-blockers and receiving nondihydropyridine calcium channel blockers due to coronary artery disease or hypertension will be excluded from the study. Concomitant treatments received by patients (and their respective doses) will not be modified during the study unless it is recommended according to current clinical practice. Patients with myocardial infarction (according to the universal definition) will receive treatment according to the current guidelines. 2.9 FOLLOW-UP Study personnel will follow patients throughout their time in hospital after surgery. They will be evaluating the patients, reviewing their medical records, and recording any outcomes. Troponins will be measured in hospital after surgery on postoperative days 1, 2, and 3. An ECG will be obtained whenever an elevated troponin is detected, as per routine practice. The heart ultrasound and/or cardiologist consult will be ordered when needed. Blood pressure and heart rate will be monitored according to routine clinical practice. The personnel will assess outcome occurrence 30 days after randomisation by telephone or approach participants during in-person visits scheduled at the enrolling site according to the postoperative care plan, with a uniform and standardised collection of outcome data in both cases. The personnel will contact all patients by telephone at 1 year after randomisation to assess outcome occurrence. Investigators can appoint unscheduled visits for any conditions if medically justified according to their knowledge. 2.10 TRIAL OUTCOMES Patient outcomes are determined throughout the trial and at the completion of the follow-up. APPENDIX II provides definitions for all outcomes. 2.10.1 Primary outcome The primary outcome is myocardial injury after non-cardiac surgery (MINS) defined as any myocardial infarction and any elevated postoperative cardiac troponin judged as resulting from myocardial ischaemia during or within 30 days after noncardiac surgery. In centres routinely using Roche’s fifth generation Elecsys hsTnT, we will use an established cut-off of 20 ng/L combined with an absolute change of ≥5 ng/L (judged as due to ischemia) to diagnose MINS. The optimal change criteria for other troponin assays will be individualized based on the cTn assay characteristics, absolute cTn concentration, the timing of measurement, and pretest probability of an acute versus chronic insult. As of the time of writing the current version of the protocol, the above-mentioned criteria represent an up-to-date state of knowledge on what constitutes a prognostically important change in troponin concentrations measured using different commercially available high sensitivity troponin assays. Myocardial injury after noncardiac surgery (MINS) is a relatively newly established diagnosis and acute myocardial injury has only recently been recognized in the most recent guidelines as a separate clinical entity (22). Given the dynamically changing landscape of evidence in this field, the definition of MINS may be refined during the conduct of the trial. If this happens, a protocol amendment may be necessary to warrant adherence to the universal definition of MINS currently in force at the time of termination of the trial. Any potential changes in the definition will be made before unblinding of data with the aim of improving the trial’s results applicability to clinical practice. 2.10.2 Secondary outcomes Secondary outcomes at 30 days include: a composite of vascular death, non-fatal MINS, non-fatal stroke, and non-fatal cardiac arrest; vascular death; MINS not fulfilling the criteria of myocardial infarction; myocardial infarction; peak troponin concentration; area under the curve troponin; days alive and at home; stroke; all-cause mortality; health-related quality of life; cancellation/postponement of surgery on the day of surgery due to HR concerns; clinically important atrial fibrillation; safety outcomes including clinically significant bradycardia, clinically significant hypotension and phosphenes. 2.10.3 Tertiary outcomes Tertiary outcomes at 30 days include: cardiac revascularization; re-hospitalization for vascular reasons; acute myocardial injury according to Fourth Universal Definition of Myocardial Infarction; non-fatal cardiac arrest; acute congestive heart failure; deep vein thrombosis/pulmonary embolism; major bleeding according to ISTH definition; bleeding independently associated with mortality after noncardiac surgery; sepsis; acute kidney injury fulfilling KDIGO criteria; acute kidney injury requiring dialysis; amputation; days outside the Intensive Care Unit; length of hospital stay; length of ICU stay; discharge destination. Tertiary outcomes at 1 year include: all-cause mortality; vascular death; myocardial infarction; non-fatal cardiac arrest; stroke; health-related quality of life; amputation; cardiac revascularization; cardiac revascularization, re-hospitalization for vascular reasons. 2.11 ADJUDICATION OF TRIAL OUTCOMES The Event Adjudication Committee consisting of physicians and researchers with expertise in perioperative medicine who are blinded to treatment allocation and who will adjudicate the primary outcome. An event adjudication plan will be developed and govern all details, definitions, and processes. We will use the decisions of the adjudication committee for all statistical analyses. 2.12 DATA ANALYSES We will analyse patients in the treatment group to which they are allocated, according to the intention-to-treat principle. A statistical analysis plan will be developed and finalised before any investigator is unblinded. A per-protocol analysis based on data from study subjects who completed the entire study period with outcome measurements available will serve as a sensitivity analysis to assess whether conclusions are sensitive to assumptions regarding the pattern of missing outcome information. 2.12.1 Main Analyses Patients’ demographics, clinical characteristics, and all outcome measurements will be summarized by median with inter-quartile range (IQR, continuous measurements) and frequency with percentage (categorical measurements). These descriptive statistics will be reported separately by study arm. For efficacy outcomes, both unadjusted and multivariable-adjusted results will be reported. All analyses will be conducted with R software. 2.12.2 Primary endpoint We will use generalized mixed-effects logistic models to compare the odds of MINS between the ivabradine group and placebo group. These models will account for the stratification by centre and include prespecified prognostically important covariates (age, chronic coronary syndrome, chronic heart failure, baseline NT-proBNP concentration, estimated GFR, peripheral artery disease, diabetes mellitus on insulin therapy) to increase the power and precision of the estimate. This adjusted analysis will be considered the primary analysis. The result will be presented as an odds ratio (OR) with 95% CI. We will infer statistical significance if the computed 2-sided p-value is less than ɑ=0.05. 2.12.3 Secondary and Tertiary endpoint For dichotomized endpoints, the same approach as described in the primary endpoint section will be used. For quantitative endpoints, we will use mixed-effects models (linear, Poisson, or negative binomial, depending on the distribution of data for a particular endpoint) according to the prespecified statistical analysis plan. All these models will account for the stratification by centre and include prespecified prognostically important covariates (see above) to increase the power and precision of the estimate. We will infer statistical significance if the computed 2-sided p-value is less than ɑ=0.05. 2.12.4 Interim analyses A Data Monitoring Committee (DMC) will meet approximately every 12 months to review safety, protocol compliance and deviation, recruitment, and follow-up rates. 2.12.4.1 The interim analysis for the early stopping for superiority The type I error probability for multiple tests of superiority will be controlled by using a Lan-DeMets (O’Brien-Fleming) alpha spending function with the two-sided type I error of α=0.05 (46). We will perform the interim formal testing at the following time points: 50% of the outcomes are observed, 75% of the outcomes are observed, and the final analysis of all observed outcomes. Two-sided tests of significance will be assumed. 2.12.4.2 The interim analysis for the early stopping for futility The conditional power based on the method of stochastic curtailment will be used for the early stopping for futility (47). This procedure evaluates the conditional probability that a particular statistical comparison will be significant at the end of the trial at the α level used in the design, given the hypothesized treatment difference and the endpoint data accumulated to date. Conditional power for the primary endpoint will be computed and provided to the DMC as part of the interim study reports and will include calculations based on the originally hypothesized treatment difference as well as the observed treatment difference up to that point in the trial. Discussion about termination of the trial will be triggered by a conditional power &lt; 0.2. 2.12.5 Missing data All the missing covariates will be imputed using the MICE (Multiple imputation using chained equations) multiple imputation procedure (48). Thirty iterations with 5 burn-in will be used for all analyses. 2.12.6 Subgroup analyses Six planned subgroup analyses will be conducted. All subgroups will be analysed using both ITT and PP populations: patients with vs. without coronary artery disease patients with vs. without congestive heart failure patients receiving vs. not receiving beta-blockers preoperatively patients with different baseline heart rates patients with a preoperative troponin &gt;99th vs. ≤99th percentile upper reference limit patients who undergo emergent/urgent vs. elective surgeries 2.13 REPORTING OF ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS 2.13.1 Definitions and reporting of adverse events and serious adverse events Serious Adverse Event (SAE) is defined as any untoward medical occurrence that at any dose: is life-threatening; or requires inpatient hospitalization or prolongation of existing hospitalization; or results in persistent or significant disability/incapacity; or is a congenital anomaly/birth defect; or is a medically important event. Suspected unexpected serious adverse reactions (SUSARs) are events that meet the following criteria: 1) suspected to be causally associated with ivabradine; 2) unexpected if the nature, severity, or outcome of the reaction(s) is not consistent with the reference information (i.e. product monograph for ivabradine); 3) serious (as defined above for an SAE); and 4) not an efficacy outcome as defined in Section regarding Trial Outcomes. Efficacy and safety outcomes will be recorded separately and not as SAEs, except if, because of the course or severity or any other feature of such events, the investigator, according to his/her best medical judgment, considers these events as exceptional in this medical condition. Hospitalizations, which were planned before inclusion in the study (e.g. elective or scheduled surgery or other interventions), will not be regarded as SAEs. This pertains also to hospitalizations which are part of the normal treatment or monitoring of the studied disease or another disease present before inclusion in the study (e.g. patient returning to the hospital for chemotherapy), and which did not result in a worsening of the disease. All SAEs need to be reported within 24 hours of knowledge of the event to the Project Office. For such events, research personnel will complete an SAE CRF in the database. The Project Office will then inform regulatory authorities in a timely manner, as necessary, according to the applicable regulations. 2.13.2 Safety reporting The independent DMC will provide oversight of patients’ safety throughout the trial by reviewing unblinded aggregate data (including all reported study outcome events and SAEs) by treatment group at regular intervals throughout the duration of the trial and ensure that the study adheres to the highest ethical standards. At any time during the trial if safety concerns arise the DMC chairperson will assemble a formal meeting of the full committee. The DMC will make their recommendations to the Steering Committee after considering all the available data. 2.14 SUBSTUDIES Substudies may be added at a later date based on the recommendation of the Project Office. A local biorepository will be established to store biological material from blood samples collected during the main project for possible substudies. We will investigate several prognostic factors (e.g. frailty, natriuretic peptide concentration, heart rate) in the context of perioperative complications and externally validate existing cardiac risk prediction tools in our sample. We also plan to evaluate the potential genetic heterogeneity of ivabradine’s treatment effect (e.g. HCN2 gene). These substudies will not be part of the main protocol and the analysis and reporting of these substudies will be separate from the main study. 2.15 TRIAL MANAGEMENT 2.15.1 Organisational structure of the PREVENT- MINS trial The National Sponsor of the trial is Jagiellonian University Medical College (JUMC). The trial is financed by the Medical Research Agency (funds obtained as a grant for research and development activities in the field of non-commercial clinical trials no. ABM/2019/1). The trial will be conducted in partnership with the Hamilton Health Sciences Corporation (“HHSC”), through its Population Health Research Institute (PHRI) in Ontario, Canada. PHRI has extensive experience in methodology and conduct of clinical trials. Professor P.J. Devereaux (PHRI, Senior Scientist) will hold the position of the Trial Chair. Project Office The Principal Investigator, Principal Co-investigators, Project Manager, Research Assistant, and Project Coordinator are responsible for the activities of the Project Office. The PREVENT-MINS Project Office, part of Jagiellonian University Medical College, is the coordinating centre for this trial and is primarily responsible for the development of the trial protocol, organization of the trial, development of the randomisation scheme, trial database, data internal consistency checks, data analyses, coordination of the trial centres, and conducting the trial. Throughout the trial, the Project Office will be in contact with all the sites. Periodic teleconferences with sites to discuss topics such as recruitment status, data quality, and outcome event reporting will be organized. Recruitment reports and periodic newsletters will be distributed among sites to keep them informed of the trial status and progress. Recruitment, drug dispensing, follow-ups and eCRF completion will be tracked by the web systems. The due-date reminder notifications and delay reminder calls will be provided to avoid any timeline disturbances. The eCRF database and IWRS will be maintained throughout the whole study. The data manager, as a part of the Project Office, will keep constant surveillance over central data consistency. Logistic issues, like drug shipments, drug disposal, biobank samples’ cryogenic transportation, all travel and meeting issues will be managed by specialized companies contracted by the Project Office. The University will aid in the management of human resources and financial issues. 2.15.2 Operations Committees The Steering Committee and Data Monitoring Committee will be formed. The Steering Committee will include:Project Principal Investigator, a representative of the Project Leader (JUMC) and a representative of the Project Partner (HHS). The Steering Committee meetings will be held on a quarterly basis. The Data Monitoring Committee will include external biostatisticians and experienced scientists. A schedule of regular (at least once a year) committee meetings will be established. 2.15.3 Site Principal Investigators All participating centres will have a site Principal Investigator (PI), and this individual is responsible for ensuring compliance with respect to the intervention, visit schedule and procedures required by the protocol. The site PI will provide all information requested in the Case Report Forms (CRFs) in an accurate and timely manner according to instructions provided. The site PI will maintain patient confidentiality with respect to all information accumulated in the course of the trial, other than that information to be disclosed by law. All investigators will be recruited among surgeons, anaesthetists, internal medicine practitioners and cardiologists who are familiar with the perioperative area and its specificity. All local PIs and co-investigators are accustomed to the Declaration of Helsinki, Good Clinical Practice (GCP), and all applicable regulations of the Polish law. 2.16 OTHER CONSIDERATIONS 2.16.1 Ethical considerations This trial will be conducted in compliance with the protocol, the Declaration of Helsinki, Good Clinical Practice (GCP), and all applicable regulations of the Polish law. Before study initiation, the Investigator must have written and dated Central Regulatory Approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych, URPL) and Jagiellonian University Bioethics Committee’s approval for the study. Following the approval by the URPL and Ethics Board, Principal Investigators from all participating sites must have: written and dated approval/favourable opinion from the Institutional Review Board (IRB; signed by director of the site or representative); Local Ethics Committee (EC) for the protocol, consent form, patients’ informed consent materials; site contract agreement with the Project office before the initiation of the study. Amendments to the protocol will also require IRB/EC and/or URPL approval. The weighing of the risks and inconveniences against the anticipated benefit to the individual trial subjects and society supports conducting the PREVENT-MINS Trial. Perioperative increases in the heart rate are common and can lead to myocardial ischaemia which is associated with an increased risk of major cardiovascular complications after surgery. Ivabradine holds substantial promise of preventing ischaemic myocardial injury. Oral administration of ivabradine in the evening prior to the procedure and twice daily for one week after surgery should not pose any significant inconvenience to the patients. Adverse events seen with ivabradine are usually benign and can be relatively easily managed in the perioperative period. There is compelling evidence that the use of ivabradine is safe in patients with chronic coronary syndrome and heart failure in the non-operative setting and preliminary data show that perioperative treatment with ivabradine is feasible and potentially beneficial in surgical patients. Therefore, the risk of experimental evaluation of ivabradine in patients having noncardiac surgery is judged as low and acceptable. 2.16.2 Data management All research personnel will undergo a training session prior to trial commencement to ensure consistency in trial procedures including data collection and reporting safety issues. Study personnel will complete CRFs through an internet platform. Data will be stored on a secure server. Source documentation supporting the information reported on the CRF will be filed at the site and made available for monitoring, IRB/EC review, and regulatory inspections, when required. The Investigator must retain all study records/files in accordance with applicable regulatory requirements. The Data Management Plan will be prepared by the study statistician in adherence to the Good Clinical Data Management Practices from the Society for Clinical Data Management. 2.16.3 Confidentiality and unblinded data All personal data collected from the study will be protected in accordance with the Polish and European data protection legislation such as the Polish Personal Information Protection Act of 10 May 2018 (Dz.U. 2018 poz. 1000) and Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data. Patients will be assigned a unique trial identification number to ensure anonymity. These ID numbers will correspond to allocation data in secure electronic files. Only the DMC and the statistician reporting to the DMC will be aware of the unblinded data until the trial is completed. Centres will be instructed to store any patient information containing names or other personal identifiers separately and identified by their ID number. Centres will secure all local databases with password-protected access systems. Individual subject medical information obtained as a result of this trial is considered confidential and disclosure to third parties is prohibited except for reasons clearly identified by the law. Medical information may be given to the subject’s personal physician or to other appropriate medical personnel responsible for the subject’s welfare. Data generated as a result of the trial are to be available for inspection on request by the participating physicians, IRB/IEC, and regulatory authorities. 2.16.4 Emergency unblinding Emergency situations may require unblinding of treatment. As the treating physician (investigator) is responsible for the medical care provided to the trial participant, the decision to break the treatment code in an emergency situation will lie solely with the investigator. Remote access (e.g. by primary or secondary back-up telephone number) will be provided to allow the blind to be broken immediately. 2.17 IMPORTANCE OF PREVENT-MINS TRIAL An estimated 100 million adults ≥45 years of age having noncardiac surgery are at risk of perioperative myocardial infarction or injury. Myocardial ischaemic injuries are a leading cause of 30-day mortality after noncardiac surgery. Increased heart rate is considered a modifiable risk factor for myocardial injury after noncardiac surgery. Perioperative beta-blockade has been shown to reduce both the heart rate and the risk of myocardial infarction, yet the potential harm associated with hypotension resulting from the initiation of beta-blockers short before noncardiac surgery precluded the widespread adoption of this strategy in preventing myocardial ischaemia. Ivabradine can be as potent as beta-blockers in slowing down the heart rate without exerting any impact on blood pressure. PREVENT-MINS trial will answer the question whether perioperative administration of ivabradine is superior to placebo in preventing myocardial injury after noncardiac surgery. 2.18 TRIAL CONDUCT DURING THE COVID-19 PANDEMIC It is recognized that the Coronavirus Disease 2019 (COVID-19) pandemic may have an impact on the conduct of the trial due to various circumstances such as, but not limited to: self-isolation/quarantine by study-site personnel; shortage of study site personnel being reassigned to COVID-19 specific activities; timely access to the study drugs due to logistics limitations caused by reduction of the number of flights or impairment of ground transport; access of the site monitors and auditors to the investigational sites. In alignment with the COVID-19 guidance documents, issued by the EMA and FDA, appropriate measures for identification and mitigation of the potential risks for the current trial associated with the COVID-19 pandemic have been planned. This guidance does not supersede any local, regional or international requirements or the clinical judgment of the investigator to protect the health and well-being of the trial subjects and site staff. If at any time the Investigator or study Sponsor would assess that the risk of the pandemic on this clinical trial may outweigh the benefits, the same as for any other reasons, study treatment period will be interrupted, and study follow-up will be conducted. The Sponsor will regularly re-assess the risks associated with the pandemic and, if needed, will take new measures when applicable: every effort should be made to adhere to protocol-specified assessments for subjects on study treatment and follow up. Modifications to protocol-required assessments should be reported to the Sponsor. Missed assessments/visits will be captured as protocol deviations, under specific notification and specification as: “COVID-19 pandemic related”. Discontinuations of study treatment and withdrawal from the study should be documented with the prefix “COVID-19-related” in detail within the subject’s source record and at the eCRF. The sponsor will perform an analysis of the number and type of deviations periodically to assess whether a protocol amendment or other modifications are needed. The Sponsor will continue to monitor the conduct and progress of the trial, and any changes will be communicated to the sites and to the health authorities according to the local guidance. Modifications made to the study conduct as a result of the COVID-19 pandemic will be summarized in the Annual reports, as well as in the clinical study report. 2.18.1 Subject Visits and Assessments The personnel will assess outcome occurrence 30 days after randomisation by telephone or approach participants during in-person visits scheduled at the enrolling site according to the postoperative care plan, with a uniform and standardised collection of outcome data in both cases. Telephone visit will be conducted to collect 1-year follow-up data. If any change in subject’s status is identified that may impact the subject’s safety, then study treatment should be interrupted until the subject can be assessed. Any changes in study treatment (frequency, interruption) needs to be clearly documented as “COVID-19-related”. All deviations from protocol-required assessments should be documented in detail within the subject’s source record and should be clearly designated as “COVID-19-related”. 2.18.2 Study Drug Supply The sites’ study drug inventory should be closely monitored. Site staff should notify the assigned site monitor if they foresee shortage in the study drug inventory or if there is any interruption in local shipping service. The Sponsor’s assigned Clinical CROs and Study Drug Logistic vendors will continue to monitor inventory of the study drug at study sites. 2.18.3 COVID-19 exposure For trial subjects who are diagnosed with COVID-19 during the active treatment period we encourage the investigators to continue administering the study drug according to the predefined schedule. Such cases should be reported to the Sponsor. 2.18.4 On-site Monitoring Visits Monitoring visits will be a combination of on-site and remote monitoring methods. In case on-site monitoring visits are not possible, as per institution policies, the sponsor’s site managers may contact the investigator to arrange remote monitoring visits. Additional on-site monitoring visits may be needed in the future to complete source data verification. 2.19 REFERENCES Weiser TG, Regenbogen SE, Thompson KD, Haynes AB, Lipsitz SR, Berry WR, et al. An estimation of the global volume of surgery: a modelling strategy based on available data. Lancet. 2008;372(9633):139-44. Semel ME, Lipsitz SR, Funk LM, Bader AM, Weiser TG, Gawande AA. Rates and patterns of death after surgery in the United States, 1996 and 2006. Surgery. 2012;151(2):171-82. Bickler SW, Spiegel DA. Global surgery–defining a research agenda. Lancet. 2008;372(9633):90-2. Writing Committee for the VSI, Devereaux PJ, Biccard BM, Sigamani A, Xavier D, Chan MTV, et al. Association of Postoperative High-Sensitivity Troponin Levels With Myocardial Injury and 30-Day Mortality Among Patients Undergoing Noncardiac Surgery. JAMA. 2017;317(16):1642-51. Vascular Events in Noncardiac Surgery Patients Cohort Evaluation Study I, Spence J, LeManach Y, Chan MTV, Wang CY, Sigamani A, et al. Association between complications and death within 30 days after noncardiac surgery. CMAJ. 2019;191(30):E830-E7. Devereaux PJ, Duceppe E, Guyatt G, Tandon V, Rodseth R, Biccard BM, et al. Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. Lancet. 2018;391(10137):2325-34. Abbott TE, Ackland GL, Archbold RA, Wragg A, Kam E, Ahmad T, et al. Preoperative heart rate and myocardial injury after non-cardiac surgery: results of a predefined secondary analysis of the VISION study. Br J Anaesth. 2016;117(2):172-81. Abbott TEF, Pearse RM, Archbold RA, Ahmad T, Niebrzegowska E, Wragg A, et al. A Prospective International Multicentre Cohort Study of Intraoperative Heart Rate and Systolic Blood Pressure and Myocardial Injury After Noncardiac Surgery: Results of the VISION Study. Anesth Analg. 2018;126(6):1936-45. Devereaux PJ, Xavier D, Pogue J, Guyatt G, Sigamani A, Garutti I, et al. Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. Ann Intern Med. 2011;154(8):523-8. Foex P, Higham H. Preoperative fast heart rate: a harbinger of perioperative adverse cardiac events. Br J Anaesth. 2016;117(3):271-4. Group PS, Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet. 2008;371(9627):1839-47. Marquis-Gravel G, Tardif JC. Ivabradine: the evidence of its therapeutic impact in angina. Core Evid. 2008;3(1):1-12. Lo Sapio P, Gensini GF, Bevilacqua S, Chiti E, Paperetti L, Pratesi C, et al. The role of ivabradine in the incidence of perioperative coronary complications in patients undergoing vascular surgery. Int J Cardiol. 2013;168(4):4352-3. Ibrahim AN, Atallah RY. Ivabradine versus propranolol given orally in microlaryngoscopic surgeries in attenuating stress response: A comparative prospective double blind randomized study. Egyptian Journal of Anaesthesia. 2016;32(4):503-11. Landesberg G, Mosseri M, Zahger D, Wolf Y, Perouansky M, Anner H, et al. Myocardial infarction after vascular surgery: the role of prolonged stress-induced, ST depression-type ischemia. J Am Coll Cardiol. 2001;37(7):1839-45. Slogoff S, Keats AS. Does perioperative myocardial ischemia lead to postoperative myocardial infarction? Anesthesiology. 1985;62(2):107-14. Shah KB, Kleinman BS, Rao TL, Jacobs HK, Mestan K, Schaafsma M. Angina and other risk factors in patients with cardiac diseases undergoing noncardiac operations. Anesth Analg. 1990;70(3):240-7. Reich DL, Bennett-Guerrero E, Bodian CA, Hossain S, Winfree W, Krol M. Intraoperative tachycardia and hypertension are independently associated with adverse outcome in noncardiac surgery of long duration. Anesth Analg. 2002;95(2):273-7, table of contents. Hartmann B, Junger A, Rohrig R, Klasen J, Jost A, Benson M, et al. Intra-operative tachycardia and peri-operative outcome. Langenbecks Arch Surg. 2003;388(4):255-60. Landesberg G, Beattie WS, Mosseri M, Jaffe AS, Alpert JS. Perioperative myocardial infarction. Circulation. 2009;119(22):2936-44. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation. 2001;104(13):1477-82. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). European Heart Journal. 2019;40(3):237-69. Beattie WS, Wijeysundera DN, Karkouti K, McCluskey S, Tait G. Does tight heart rate control improve beta-blocker efficacy? An updated analysis of the noncardiac surgical randomized trials. Anesth Analg. 2008;106(4):1039-48, table of contents. Devereaux PJ, Sessler DI, Leslie K, Kurz A, Mrkobrada M, Alonso-Coello P, et al. Clonidine in patients undergoing noncardiac surgery. N Engl J Med. 2014;370(16):1504-13. Sulfi S, Timmis AD. Ivabradine – the first selective sinus node I(f) channel inhibitor in the treatment of stable angina. Int J Clin Pract. 2006;60(2):222-8. G R, Singh D, Kabra A. Attenuation of haemodynamic response to laryngoscopy and endotracheal intubation using intra-oral ivabradine: a clinical study. Journal of Evolution of Medical and Dental Sciences. 2014;3:9944-55. Hellenbart EL, Griffin T, DiDomenico RJ. Beyond Heart Failure and Ischemic Heart Disease: A Scoping Review of Novel Uses of Ivabradine in Adults. Pharmacotherapy. 2020;40(6):544-64. Arora V, Awasthi G, Singh RB, Singh V. Study of Attenuation of Hemodynamic Response to Laryngoscopy and Endotracheal Intubation using Intra-oral Ivabradine. Anesth Essays Res. 2019;13(1):138-43. Mathur VG, Ankit; Jethawa, Durga; Sharma, S.P.; Verma, Kalpana;. Comparison of Oral Ivabradine, Oral Metoprolol and Placebo to Attenuate the Stress Response in Nasal and Laryngeal Surgeries: A Prospective, Randomized, Double Blind Study. Int J Med Res Prof. 2019;5(2):115-23. Borer JS, Fox K, Jaillon P, Lerebours G, Ivabradine Investigators G. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107(6):817-23. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K, Investigators I. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26(23):2529-36. Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs. 2007;67(3):393-405. Tardif JC, Ponikowski P, Kahan T, Investigators AS. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009;30(5):540-8. Fox K, Ford I, Steg PG, Tendera M, Ferrari R, Investigators B. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9641):807-16. Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371(12):1091-9. Ferrari R, Pavasini R, Camici PG, Crea F, Danchin N, Pinto F, et al. Anti-anginal drugs-beliefs and evidence: systematic review covering 50 years of medical treatment. Eur Heart J. 2019;40(2):190-4. Mengesha HG, Weldearegawi B, Petrucka P, Bekele T, Otieno MG, Hailu A. Effect of ivabradine on cardiovascular outcomes in patients with stable angina: meta-analysis of randomized clinical trials. BMC Cardiovasc Disord. 2017;17(1):105. Tanboga IH, Topcu S, Aksakal E, Gulcu O, Aksakal E, Aksu U, et al. The Risk of Atrial Fibrillation With Ivabradine Treatment: A Meta-analysis With Trial Sequential Analysis of More Than 40000 Patients. Clin Cardiol. 2016;39(10):615-20. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875-85. Borer JS, Swedberg K, Komajda M, Ford I, Tavazzi L, Bohm M, et al. Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris. Cardiology. 2017;136(2):138-44. Bohm M, Borer J, Ford I, Gonzalez-Juanatey JR, Komajda M, Lopez-Sendon J, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol. 2013;102(1):11-22. Fox K, Komajda M, Ford I, Robertson M, Bohm M, Borer JS, et al. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. Eur Heart J. 2013;34(29):2263-70. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-77. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200. Smilowitz NR, Redel-Traub G, Hausvater A, Armanious A, Nicholson J, Puelacher C, et al. Myocardial Injury After Noncardiac Surgery: A Systematic Review and Meta-Analysis. Cardiol Rev. 2019;27(6):267-73. DeMets DL, Lan KK. Interim analysis: the alpha spending function approach. Stat Med. 1994;13(13-14):1341-52; discussion 53-6. Halperin M, Lan KK, Ware JH, Johnson NJ, DeMets DL. An aid to data monitoring in long-term clinical trials. Control Clin Trials. 1982;3(4):311-23. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011;30(4):377-99. 2.20 PREVENT-MINS Trial Procedure Schedule Time Period Screening Baseline IN HOSPITAL Follow-up During Hospitalization At Discharge 30 days 1 year Eligibility Assessment x Informed Consent x Randomisation x Demographics x Medical History x Concomitant Medications x x x x x x Labs x x x Biobank x x Intervention x1 Surgery Details x x Vitals signs x x x x Troponin x x2 QOL3 form x x x ASA PS4, DASI5, CFS6 x Outcome Event x x x x study drug administration up to 7 days after surgery in hospitalised patients (treatment discontinued in case of hospital discharge) Troponins will be measured daily up to 3 days after surgery Quality of Life American Society of Anaesthesiologist Physical Status Classification System Duke Activity Status Index Clinical Frailty Scale 2.21 TRIAL FLOW CHART 2.22 APPENDIX II. PREVENT-MINS Outcome Definitions Myocardial injury after non-cardiac injury (MINS) is defined as any myocardial infarction and any acutely elevated postoperative cardiac troponin judged as resulting from myocardial ischaemia during or within 30 days after noncardiac surgery. In centres routinely using Roche’s fifth-generation Elecsys hsTnT, we will use an established cut-off of 20 ng/L combined with an absolute change of ≥5 ng/L (judged as due to ischaemia) to diagnose MINS. The optimal change criteria for other troponin assays will be individualized based on the cTn assay characteristics, absolute cTn concentration, the timing of measurement, and pretest probability of an acute versus chronic insult. Vascular death is defined as a death with a vascular cause and includes those deaths following a myocardial infarction, sudden cardiac arrest, stroke, cardiac revascularization procedure (i.e. percutaneous coronary intervention - PCI or coronary artery bypass graft [CABG] surgery), pulmonary embolus, cardiovascular haemorrhage, or deaths due to an unknown cause. Cardiovascular haemorrhage includes a non-stroke intracranial haemorrhage, non- procedural or non-traumatic vascular rupture (e.g. aortic aneurysm), or haemorrhage causing cardiac tamponade. All-cause mortality includes both vascular and non-vascular death. Non-vascular death is defined as any death due to a clearly documented non-vascular cause (e.g. trauma, infection, malignancy). Myocardial infarction is defined according to the Fourth Universal Definition of Myocardial Infarction: Acute myocardial injury with clinical evidence of acute myocardial ischaemia and with detection of a rise and/or fall of cTn values with at least one value above the 99th percentile URL and at least one of the following: Symptoms of myocardial ischaemia; New ischaemic ECG changes; Development of pathological Q waves; Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischaemic aetiology; Identification of a coronary thrombus by angiography or autopsy. Cardiac death in patients with symptoms suggestive of myocardial ischaemia and presumed new ischaemic ECG changes before cTn values become available or abnormal. Coronary intervention-related MI is arbitrarily defined by an elevation of cTn values more than five times the 99th percentile URL in patients with normal baseline values. In patients with elevated pre-procedure cTn in whom the cTn level is stable (&lt; 20% variation) or falling, the post-procedure cTn must rise by &gt;20%. However, the absolute post-procedural value must still be at least five times the 99th percentile URL. In addition, one of the following elements is required: (I) New ischaemic ECG changes; (II) Development of new pathological Q waves; (III) Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischaemic aetiology; (IV) Angiographic findings consistent with a procedural flow-limiting complication such as coronary dissection, occlusion of a major epicardial artery or a side branch occlusion/thrombus, disruption of collateral flow, or distal embolization. Stent thrombosis associated with myocardial infarction when detected by coronary angiography or autopsy in the setting of myocardial ischaemia and with a rise and/or fall of cardiac biomarker values with at least one of value above the 99th percentile URL. CABG-related MI is arbitrarily defined as elevation of cTn values &gt; 10 times the 99th percentile URL in patients with normal baseline cTn values. In patients with elevated pre-procedure cTn in whom cTn levels are stable (≤20% variation) or falling, the postprocedure cTn must rise by &gt; 20%. However, the absolute postprocedural value still must be &gt; 10 times the 99th percentile URL. In addition, one of the following elements is required: (I)Development of new pathological Q waves; (II) Angiographic documented new graft occlusion or new native coronary artery occlusion; (III) Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischaemic aetiology. Non-fatal cardiac arrest is defined as successful resuscitation from either documented or presumed ventricular fibrillation, sustained ventricular tachycardia, asystole, or pulseless electrical activity (PEA) requiring cardiopulmonary resuscitation, pharmacological therapy, or cardiac defibrillation. Acute myocardial injury according to the Fourth Universal Definition of Myocardial Infarction is defined according to the Fourth Universal Definition of Myocardial Infarction as a detection of an elevated cTn value above the 99th percentile URL with a rise and/or fall of cTn values. Peak troponin concentration is defined as a peak cTn concentration measured in the postoperative period. Area under the curve troponin is defined as total cTn release measured as area under the Troponin-Time curve. Clinically significant bradycardia is defined as bradycardia that required a pacemaker, sympathomimetic agent, atropine, or study drug discontinuation. Clinically significant hypotension is defined as systolic blood pressure &lt;90 mm Hg that required fluid resuscitation, intra-aortic balloon pump, a vasoactive agent, or study drug discontinuation. Phosphene is defined as the phenomenon of seeing light without light actually entering the eye. Cardiac revascularization includes PCI and CABG surgery. Re-hospitalization for vascular reasons is defined as a re-hospitalization due to myocardial infarction, nonfatal cardiac arrest, stroke, congestive heart failure, ischaemic symptoms with ST or T wave changes on an ECG, cardiac arrhythmia, cardiac revascularization procedure, amputation, peripheral arterial thrombosis, DVT, pulmonary embolus, any vascular surgery, or cardiovascular haemorrhage. Acute kidney injury fulfilling KDIGO criteria is defined as an increase in serum creatinine concentration by either an increase of ≥26.5 μmol/L (≥0.3 mg/dL) within 48 hours or an increase of ≥50% from baseline within 7 days or urine output &lt;0.5 mL/kg/h for 6 hours. Acute kidney injury requiring dialysis is defined as an acute kidney injury leading to the use of a haemodialysis machine or peritoneal dialysis apparatus. Stroke is defined as a new focal neurological deficit thought to be vascular in origin with signs or symptoms lasting more than 24 hours or leading to death. Stroke will be sub-classified into haemorrhagic and non-haemorrhagic stroke. Health-related quality of life will be evaluated using a validated Polish version of EuroQoL 5 Dimension (EQ-5D; five-level version with visual analogue scale) tool. Length of hospital stay is defined as the number of nights in the hospital. Length of ICU stay is defined as the number of nights in the ICU. Discharge destination is defined as a destination of patient`s discharge from the hospital (i.e. home or long-term care facility or other). Days outside the Intensive Care Unit is defined as the number of nights outside the Intensive Care Unit within 30 days after the index procedure. Days alive and at home is defined as the number of days when a patient is alive and out of hospital within 30 days after the index procedure_._ Acute congestive heart failure is defined as an episode characterized by at least one of the following clinical signs (i.e. any of the following signs: elevated jugular venous pressure, respiratory rales/crackles, crepitations, or presence of S3) and at least one of the following: (I) Radiographic findings (i.e. vascular redistribution, interstitial pulmonary oedema, or frank alveolar pulmonary oedema) OR (II) Heart failure treatment implemented with diuretics with documented clinical improvement. Deep vein thrombosis/pulmonary embolism is defined as a symptomatic or an asymptomatic episode of deep vein thrombosis or pulmonary embolism. The diagnosis of deep vein thrombosis requires evidence of thrombus presence in deep veins of upper or lower extremities defined as any of the following: (I) a persistent intraluminal filling defect on contrast venography (including on computed tomography), (II) noncompressibility of one or more venous segments on B mode compression ultrasonography, or (III) a clearly defined intraluminal filling defect on doppler imaging in a vein that cannot have compressibility assessed (e.g., iliac, inferior vena cava, subclavian). Diagnosis of pulmonary embolism requires any one of the following: (i) A high probability ventilation/ perfusion lung scan (ii) An intraluminal filling defect of segmental or larger artery on a helical CT scan (iii) An intraluminal filling defect on pulmonary angiography (iv) A positive diagnostic test for deep venous thrombosis (e.g. positive compression ultrasound) and one of the following: (a) Non-diagnostic (i.e. low or intermediate probability) ventilation/perfusion lung scan (b) Non-diagnostic (i.e. subsegmental defects or technically inadequate study) helical CT scan. Major bleeding according to ISTH definition is a bleeding meeting any of the following criteria: (I) Fatal bleeding; (II) Bleeding that is symptomatic and occurs in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, pericardial, in a non-operated joint, or intramuscular with compartment syndrome, assessed in consultation with the surgeon; (III) Extrasurgical site bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells, with temporal association within 24–48 h to the bleeding; (IV) Surgical site bleeding that requires a second intervention - open, arthroscopic, endovascular – or a hemarthrosis of sufficient size as to interfere with rehabilitation by delaying mobilization or delayed wound healing, resulting in prolonged hospitalization or a deep wound infection, or (V) Surgical site bleeding that is unexpected and prolonged and/ or sufficiently large to cause hemodynamic instability, as assessed by the surgeon. There should be an associate fall in hemoglobin level of 20 g/L (1.24 mmol/L), or transfusion, indicated by the bleeding, of at least two units of whole blood or red cells, with temporal association within 24 h to the bleeding. Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS) is defined as bleeding that leads to a postoperative haemoglobin &lt;70 g/L, leads to blood transfusion, or is judged to be the immediate cause of death. Clinically important atrial fibrillation is defined as a new onset of atrial fibrillation or atrial flutter of any duration on an ECG or rhythm strip, which results in angina, congestive heart failure, symptomatic hypotension, or requires treatment with a rate controlling drug, antiarrhythmic drug, or electrical cardioversion. Sepsis is defined as an increase in SOFA score of 2 or more, with evidence of infection. This outcome includes septic shock defined as sepsis with shock (vasopressor requirement to maintain a mean arterial pressure of 65 mm Hg or greater and serum lactate level greater than 2 mM [&gt;18 mg/dl] in the absence of hypovolaemia). Infection is defined as a pathologic process caused by the invasion of normally sterile tissue or fluid or body cavity by pathogenic or potentially pathogenic organisms. Amputation is defined as an amputation procedure, or auto amputation subsequent to the initial surgery. Cancellation/postponement of surgery on the day of surgery due to HR concerns is defined as cancellation or postponement of index surgery on the day of the index surgery attributed to concerns about heart rate as assessed by treating physician (anaesthesiologist or surgeon). 2.23 APPENDIX III. PREVENT-MINS Sample Size Calculation Power and sample size estimations were based on a group sequential design with 2 interim analyses conducted when 50% and 75% outcomes were collected. An overall two-sided type I error rate of α=0.05 will be achieved by using the Lan-DeMets (O’Brien-Fleming) alpha spending function. We anticipate that 2500 participants will be recruited, with a 2% dropout rate over the study period. The table below presents the statistical power of the trial for different plausible scenarios of the MINS rate in the control group assuming a 1:1 allocation ratio. Dropout Rate (N= Participants retained) Event rate in control group 20% Rate reduction in intervention group (RR=0.8) 25% Rate reduction in intervention group(RR=0.75) 30% Rate reduction in intervention group(RR=0.7) Event Rate Power Event Rate Power Event Rate Power 0% (N=2500) 0.16 12.8% 61.6% 12.0% 81.4% 11.2% 93.4% 0.18 14.4% 67.6% 13.5% 86.4% 12.6% 96.1% 0.2 16.0% 73.1% 15.0% 90.3% 14.0% 97.7% 2% (N=2450) 0.16 12.8% 60.7% 12.0% 80.7% 11.2% 93.0% 0.18 14.4% 63.0% 13.5% 82.7% 12.6% 94.1% 0.2 16.0% 68.6% 15.0% 87.1% 14.0% 96.4% "],["euroqol-group-eq-5d-pl.html", "3 EuroQol Group EQ-5D PL", " 3 EuroQol Group EQ-5D PL "],["asa-ps.html", "4 ASA PS", " 4 ASA PS ASA PS Classification Definition Adult Examples, Including, but not Limited to: Pediatric Examples, Including but not Limited to: Obstetric Examples, Including but not Limited to: ASA I A normal healthy patient Healthy, non-smoking, no or minimal alcohol use Healthy (no acute or chronic disease), normal BMI percentile for age ASA II A patient with mild systemic disease Mild diseases only without substantive functional limitations. Current smoker, social alcohol drinker, pregnancy, obesity (30&lt;BMI&lt;40), well-controlled DM/HTN, mild lung disease Asymptomatic congenital cardiac disease, well controlled dysrhythmias, asthma without exacerbation, well controlled epilepsy, non-insulin dependent diabetes mellitus, abnormal BMI percentile for age, mild/moderate OSA, oncologic state in remission, autism with mild limitations Normal pregnancy*, well controlled gestational HTN, controlled preeclampsia without severe features, diet-controlled gestational DM. ASA III A patient with severe systemic disease Substantive functional limitations; One or more moderate to severe diseases. Poorly controlled DM or HTN, COPD, morbid obesity (BMI ≥40), active hepatitis, alcohol dependence or abuse, implanted pacemaker, moderate reduction of ejection fraction, ESRD undergoing regularly scheduled dialysis, history (&gt;3 months) of MI, CVA, TIA, or CAD/stents. Uncorrected stable congenital cardiac abnormality, asthma with exacerbation, poorly controlled epilepsy, insulin dependent diabetes mellitus, morbid obesity, malnutrition, severe OSA, oncologic state, renal failure, muscular dystrophy, cystic fibrosis, history of organ transplantation, brain/spinal cord malformation, symptomatic hydrocephalus, premature infant PCA &lt;60 weeks, autism with severe limitations, metabolic disease, difficult airway, long term parenteral nutrition. Full term infants &lt;6 weeks of age. Preeclampsia with severe features, gestational DM with complications or high insulin requirements, a thrombophilic disease requiring anticoagulation. ASA IV A patient with severe systemic disease that is a constant threat to life Recent (&lt;3 months) MI, CVA, TIA or CAD/stents, ongoing cardiac ischemia or severe valve dysfunction, severe reduction of ejection fraction, shock, sepsis, DIC, ARD or ESRD not undergoing regularly scheduled dialysis Symptomatic congenital cardiac abnormality, congestive heart failure, active sequelae of prematurity, acute hypoxic-ischemic encephalopathy, shock, sepsis, disseminated intravascular coagulation, automatic implantable cardioverter-defibrillator, ventilator dependence, endocrinopathy, severe trauma, severe respiratory distress, advanced oncologic state. Preeclampsia with severe features complicated by HELLP or other adverse event, peripartum cardiomyopathy with EF &lt;40, uncorrected/decompensated heart disease, acquired or congenital. ASA V A moribund patient who is not expected to survive without the operation Ruptured abdominal/thoracic aneurysm, massive trauma, intracranial bleed with mass effect, ischemic bowel in the face of significant cardiac pathology or multiple organ/system dysfunction Massive trauma, intracranial hemorrhage with mass effect, patient requiring ECMO, respiratory failure or arrest, malignant hypertension, decompensated congestive heart failure, hepatic encephalopathy, ischemic bowel or multiple organ/system dysfunction. Uterine rupture. ASA VI A declared brain-dead patient whose organs are being removed for donor purposes *Although pregnancy is not a disease, the parturient’ s physiologic state is significantly altered from when the woman is not pregnant, hence the assignment of ASA 2 for a woman with uncomplicated pregnancy. **The addition of “E” denotes Emergency surgery: (An emergency is defined as existing when delay in treatment of the patient would lead to a significant increase in the threat to life or body part) "],["duke-activity-status-index-dasi.html", "5 Duke Activity Status Index (DASI)", " 5 Duke Activity Status Index (DASI) "],["clinical-frailty-scale-cfs.html", "6 Clinical Frailty Scale (CFS)", " 6 Clinical Frailty Scale (CFS) "],["404.html", "Page not found", " Page not found The page you requested cannot be found (perhaps it was moved or renamed). You may want to try searching to find the page's new location, or use the table of contents to find the page you are looking for. "]]
